

<p style="text-align: right;">Page 234</p> <p>1 A. Yes, I believe they didn't receive an answer 2 from me.</p> <p>3 Q. And after September 15th, 2001, did they receive 4 an answer from you?</p> <p>5 A. I don't believe they did.</p> <p>6 Q. Did you discuss this -- do you recall discussing 7 this with Mr. Herrera?</p> <p>8 A. I do not recall discussing it with him. (Copy of E-mail to Mr. Price, et al. from Mr. Simmons and Attachment were marked Exhibit Number 47 for identification.)</p> <p>13 Q. I show you this document and ask you if you 14 recognize it.</p> <p>15 A. No, I do not recognize this document at all.</p> <p>16 Q. Does this refer to the earlier exhibit that I 17 showed you about two or three exhibits ago where 18 there was some tax planning issue in your words?</p> <p>19 A. I believe it is.</p> <p>20 Q. Okay.</p> <p>21 A. It seems to fall in line with the tax planning discussions that we were beginning to have.</p> <p>23 Q. Okay. So am I correct that on October 23rd, 24 2001, just three weeks or so before you give</p>	<p style="text-align: right;">Page 234</p> <p>1 not seen any documents transferring anything.</p> <p>2 Q. If you look at the second page of this exhibit, 3 it's got --</p> <p>4 MR. STEWART: We're still on Exhibit 5 47?</p> <p>6 MR. BOSTWICK: Yes.</p> <p>7 Q. It's a memo, dated October 19th, 2001, correct?</p> <p>8 A. Yes.</p> <p>9 Q. And there's a current structure, which is a few 10 weeks before the notice to Ethypharm, and that's 11 a pretty simple, straightforward structure, 12 correct; Bentley Pharmaceuticals at the top, 13 Laboratorios Belmac underneath?</p> <p>14 A. This is a proposed or tentative, for-discussion- purposes structure.</p> <p>16 Q. Well, that -- I think the title on that says Current Structure. Do you see that?</p> <p>18 A. What page are you on?</p> <p>19 Q. Maybe you're on the wrong page. 3093. In other 20 words, on 3093, two, three weeks before or -- 21 three weeks or so before the notice to 22 Ethypharm, this structure for the IP and the tax 23 relating to the intellectual property currently 24 under development in Spain is a relatively</p>
<p style="text-align: right;">Page 235</p> <p>1 notice to Ethypharm, there is an effort to 2 exchange preliminary and tentative tax planning 3 structures for the intellectual property 4 currently under development in Spain?</p> <p>5 A. I don't know.</p> <p>6 Q. So I asked you before who actually owned the 7 intellectual property, whether it was the 8 know-how, the patents, et cetera, and I 9 understand that Laboratorios Belmac filed for 10 the patents, for example, but do you know to a 11 certainty sitting here today as to which one of 12 these subsidiaries or parents or entities 13 actually owns the intellectual property that was 14 under development in Spain in October 2001 15 relating to omeprazole and lansoprazole?</p> <p>16 A. I believe Laboratorios Belmac.</p> <p>17 Q. Do you know that to a certainty?</p> <p>18 A. Not 100 percent, but I feel quite comfortable 19 that it is Laboratorios Belmac.</p> <p>20 Q. Why do you think that?</p> <p>21 A. Because the inventors of the IP were employees 22 of Laboratorios Belmac. It was filed by 23 Laboratorios Belmac. It makes logical sense 24 that it would be Laboratorios Belmac, and I have</p>	<p style="text-align: right;">Page 237</p> <p>1 simple, straightforward structure, correct?</p> <p>2 A. Yes.</p> <p>3 Q. Bentley on top, Laboratorios Belmac underneath, 4 correct?</p> <p>5 A. Yes.</p> <p>6 Q. Can you explain to me the proposed structure of 7 what's going to happen with the intellectual 8 property under development in Spain, which is on 9 the next page, 3094?</p> <p>10 A. Not a possibility. I could not explain this. 11 As I said, I had not seen this. It was part of 12 tax planning, the potential ways for IP to be 13 held. It never came up to my level for review 14 and explanation.</p> <p>15 Q. Okay. So there's -- it does say on that page, 16 3094, that there'd be a transfer of IP to this 17 Swiss branch of a Spanish holding company, and 18 you wind your way up to Bentley Pharmaceuticals 19 at the top of this food chain. Do you see that?</p> <p>20 MR. STEWART: Are you asking him now 21 to simply repeat what he sees in the piece of 22 paper? Because he's already told you he has no 23 knowledge of this document.</p> <p>24 Q. I'm just asking if my characterization of that</p>

60 (Pages 234 to 237)

<p style="text-align: right;">Page 238</p> <p>1 graph appears to be correct to you.</p> <p>2 MR. STEWART: Objection. The document 3 speaks for itself. You have it as an exhibit.</p> <p>4 A. I don't know. I don't know this graph.</p> <p>5 Q. Whose idea was it to change the structure -- the 6 proposed European structure around October 2001?</p> <p>7 A. I don't think it was anybody's plan or proposal. 8 It was part of tax planning, what should we be 9 looking for in the future and should we be 10 exploring what would make sense for all the 11 intellectual property. This never went 12 anywhere. It never came to me for discussion.</p> <p>13 Q. When you say it never went anywhere, was a 14 different structure ultimately implemented?</p> <p>15 A. No.</p> <p>16 Q. Pardon?</p> <p>17 A. No. There's no other structure implemented 18 along these lines at all.</p> <p>19 Q. Okay. So is it your understanding that the 20 current structure that exists today is the 21 structure that's set forth on Page 3093?</p> <p>22 A. Yes. We have recently talked about other 23 possibilities with our Irish subsidiary that has 24 been formed within the last year.</p>	<p style="text-align: right;">Page 240</p> <p>1 THE WITNESS: 45?</p> <p>2 MR. STEWART: If you want to just hand 3 me the whole thing.</p> <p>4 (Documents handed the counsel.)</p> <p>5 MR. STEWART: Thank you.</p> <p>6 A. Yes.</p> <p>7 Q. Okay. You recognize that to be a press release 8 issued by Bentley on November 14th, 2001?</p> <p>9 A. Yes.</p> <p>10 Q. Why did you issue -- why did Bentley issue a 11 press release about the filing of patents 12 relating to omeprazole and lansoprazole on the 13 same day they terminated -- they gave notice of 14 termination of the agreement with Ethypharm?</p> <p>15 A. I don't believe there was any connection nor any 16 contemplation. I would have to say to the best 17 of my knowledge that would be only by 18 coincidence.</p> <p>19 Q. So that's sheer coincidence?</p> <p>20 A. Yes.</p> <p>21 Q. And is this statement that Bentley 22 Pharmaceuticals files for new patents, is that 23 true?</p> <p>24 A. It says, "Announced through its wholly owned</p>
<p style="text-align: right;">Page 239</p> <p>1 Q. When was -- what is it, Pharma -- Pharma de 2 Espana created, the wholly owned subsidiary of 3 Bentley, which is a Delaware corporation?</p> <p>4 A. I don't know the date. It was formed -- it was 5 formed in contemplation of possible sale of the 6 subsidiary.</p> <p>7 Q. Was it around this time period, 2001, or before 8 or after?</p> <p>9 A. I really don't know.</p> <p>10 Q. Is Mike Price a better person to ask about the 11 details of this arrangement?</p> <p>12 A. Yes.</p> <p>13 Q. We have looked at the termination letter or -- a 14 termination letter dated November 14th, and I 15 want to show you a document that has the same 16 date on it.</p> <p>17 (Press Release, dated November 14, 2001 18 was marked Exhibit Number 48 for 19 identification.)</p> <p>20 Q. I'll ask you to take a look at that and see if 21 you recognize it.</p> <p>22 MR. STEWART: While the witness is 23 looking, can I take -- can I have Exhibit 45, 24 please?</p>	<p style="text-align: right;">Page 241</p> <p>1 Spanish subsidiary, Laboratorios Belmac."</p> <p>2 Q. So that Bentley filed these through its wholly 3 owned Spanish subsidiary; that's correct?</p> <p>4 A. No. It says, "Bentley Pharmaceuticals, a drug 5 delivery company with commercial presence in 6 Europe, announced today that through its wholly 7 owned Spanish subsidiary," meaning the Spanish 8 subsidiary filed, Laboratorios Belmac, "new 9 patents."</p> <p>10 Q. Let's look at the title of that press release 11 first. The title says Bentley Pharmaceuticals 12 Files For New Patents. Do you see that?</p> <p>13 A. Yes.</p> <p>14 Q. And is that a true statement that Bentley 15 Pharmaceuticals files for new patents?</p> <p>16 A. On a consolidated basis, when you consider the 17 subsidiaries in there, yes, it is.</p> <p>18 Q. In there what?</p> <p>19 A. In Bentley Pharmaceuticals, on a consolidated 20 basis.</p> <p>21 Q. Meaning viewing the group as a whole, Bentley 22 and its subsidiaries?</p> <p>23 A. Bentley and its subsidiaries -- Bentley together 24 with its subsidiaries or through its</p>

61 (Pages 238 to 241)

<p>1 subsidiaries.</p> <p>2 Q. And is that the impression you're trying to give 3 the public and the shareholders, that Bentley 4 acts as a consolidated whole?</p> <p>5 A. No. I think we were very clear to the 6 shareholders. We clearly said in the first 7 paragraph that Bentley, a publicly traded 8 company, BNT, is a drug delivery company with a 9 commercial presence in Europe, and through its 10 wholly owned subsidiary, Spanish subsidiary.</p> <p>11 Very clear.</p> <p>12 Q. It doesn't say, "and through." It says, 13 "Bentley Pharmaceuticals, Inc."</p> <p>14 A. Right. It doesn't say "and." Bentley.</p> <p>15 Q. -- "through its wholly owned subsidiary," 16 correct?</p> <p>17 A. Correct.</p> <p>18 Q. So that's a truer statement than Bentley 19 Pharmaceuticals files for new patents; is that 20 what you're saying?</p> <p>21 A. When you read the text, it's very clear, very 22 distinct: The title is a summary piece that's 23 just put up above. Bentley Pharmaceuticals in 24 the title because that's the publicly traded</p>	<p>Page 242</p> <p>1 understand everything about a specific drug and 2 direct someone to file a patent on it, correct?</p> <p>3 MR. STEWART: Objection.</p> <p>4 A. Yes.</p> <p>5 Q. Isn't that what's happening here?</p> <p>6 A. No.</p> <p>7 Q. This is not -- it's your position, I take it, 8 that this filing of the four patents relating to 9 omeprazole and lansoprazole is not a part of a 10 coordinated strategy designed by Bentley 11 headquarters in the U.S.?</p> <p>12 A. It is not designed by Bentley headquarters in 13 the U.S.</p> <p>14 Q. When was the press release drafted? Do you 15 know?</p> <p>16 A. I don't know.</p> <p>17 Q. Who drafts them?</p> <p>18 A. Sometimes I get involved. Sometimes Mike Price. 19 Other times it could be our investor relations 20 organization.</p> <p>21 Q. And there's a benefit to Bentley in Laboratorios 22 Belmac filing these four patents; isn't that 23 correct?</p> <p>24 A. Yes.</p>
<p>1 company, and then the subject, what is the news, 2 is new patents for omeprazole and lansoprazole. 3 Very typical press release.</p> <p>4 Q. Do you believe it is fair to say that Bentley 5 Pharmaceuticals was -- strike that. Do you feel 6 that it's fair to say that Laboratorios Belmac 7 was acting in concert with Bentley 8 Pharmaceuticals' strategy in filing these four 9 new patents for omeprazole and lansoprazole?</p> <p>10 A. No. Laboratorios Belmac was conducting its own 11 strategy.</p> <p>12 Q. And Bentley Pharmaceuticals had no input, no 13 direction or control over Laboratorios Belmac's 14 strategy to file four new patents for improved 15 orally delivered product, including omeprazole 16 and lansoprazole; is that correct?</p> <p>17 A. There is nobody within Bentley Pharmaceuticals 18 that has expertise in oral drug delivery 19 processes or products or patents to be able to 20 guide or interact with Laboratorios Belmac. 21 Hence, Laboratorios Belmac out of necessity must 22 act on its own and with its advisors and its own 23 patent counsels.</p> <p>24 Q. Well, sir, you could easily as a CEO not</p>	<p>Page 243</p> <p>1 about the benefits to Bentley, correct?</p> <p>3 A. Yes.</p> <p>4 Q. Who created your quotation? Is that you talking 5 to your press people and they're quoting you?</p> <p>6 A. I don't know in this case. Sometimes the IR 7 group writes what they feel it is, and then we 8 edit it. Other times, we might change some 9 words or insert words. I don't know in this 10 particular case.</p> <p>11 Q. Was this given to you for your review, this 12 press release?</p> <p>13 A. Yes.</p> <p>14 Q. So you approved of its contents?</p> <p>15 A. Yes.</p> <p>16 (Confidentiality Agreement was marked 17 Exhibit Number 49 for identification.)</p> <p>18 Q. I'm going to show you Exhibit 49, which is 19 another document dated the very same day, 20 November 14th, 2001, and it's a confidentiality 21 agreement between Laboratorios Belmac and 22 PharmAlliance. Do you see that?</p> <p>23 A. Yes.</p> <p>24 Q. And this relates to omeprazole; does it not?</p>

<p style="text-align: right;">Page 246</p> <p>1 A. Yes.</p> <p>2 Q. And PharmAlliance was a client of Ethypharm's,</p> <p>3 correct?</p> <p>4 A. Yes.</p> <p>5 Q. So the very same day you give notice of</p> <p>6 termination but haven't yet terminated the</p> <p>7 contract with Ethypharm and the very same day</p> <p>8 there's an announcement by Bentley of the new</p> <p>9 patents, Laboratorios Belmac also enters into a</p> <p>10 confidentiality agreement relating to</p> <p>omeprazole; is that correct?</p> <p>12 MR. STEWART: Objection as to the</p> <p>13 characterization of the use of the word "you,"</p> <p>14 which is vague and unspecific.</p> <p>15 A. Adolfo Herrera apparently entered into an</p> <p>16 agreement on this date with PharmAlliance.</p> <p>17 Q. Do you know anything about this?</p> <p>18 A. I was not aware of it.</p> <p>19 Q. Have you ever seen this document before?</p> <p>20 A. I don't recall seeing this.</p> <p>21 Q. You're aware that PharmAlliance was a customer</p> <p>22 of Ethypharm?</p> <p>23 A. Yes.</p> <p>24 Q. Does this surprise you?</p>	<p style="text-align: right;">Page 248</p> <p>1 listed as the Bentley -- on the Bentley project</p> <p>status report, dated November 20th, 2001?</p> <p>3 A. Yes.</p> <p>4 Q. And the action to be taken is Jordan and Bob G.</p> <p>5 to review patent issues, Jordan to have more</p> <p>6 oversight on patents. Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. And Jordan, again, is Bentley's attorney, not</p> <p>Belmac's attorney, correct?</p> <p>10 A. Yes.</p> <p>11 Q. Who is Bob G.?</p> <p>12 A. Bob G. is head of research, responsible for the</p> <p>patent -- patents of Bentley.</p> <p>14 Q. So you're getting Bentley lawyers more involved</p> <p>in the Spanish patent situation; is that</p> <p>correct?</p> <p>17 MR. STEWART: Objection.</p> <p>18 A. No.</p> <p>19 Q. They're going to review the patent issues,</p> <p>20 correct?</p> <p>21 A. If you remember, we were looking at tax planning</p> <p>and IP, and Jordan was in charge of doing that.</p> <p>23 This is very consistent with what we talked</p> <p>about previously.</p>
<p style="text-align: right;">Page 247</p> <p>1 A. Does this surprise me?</p> <p>2 Q. Yes.</p> <p>3 A. No.</p> <p>4 Q. Is this something that you think is acceptable</p> <p>5 and appropriate?</p> <p>6 MR. STEWART: Objection.</p> <p>7 A. Yes.</p> <p>8 Q. Okay. Let me show you another document.</p> <p>(Copy of E-mail to Mr. Murphy, et al.</p> <p>from Mr. Fitzgibbons, dated November 20,</p> <p>2001, and Attachment were marked Exhibit</p> <p>Number 50 for identification.)</p> <p>13 Q. I ask if you recognize that document as a</p> <p>project status report for Bentley</p> <p>Pharmaceuticals, dated November 20th, 2001, with</p> <p>a cover e-mail?</p> <p>17 A. Yes.</p> <p>18 Q. And you're one of the recipients on that e-mail</p> <p>of November 30th, 2001?</p> <p>20 A. Yes.</p> <p>21 Q. This is one of these operation reports or</p> <p>project status reports, correct?</p> <p>23 A. Yes.</p> <p>24 Q. If you look at 15, you see the new patents all</p>	<p style="text-align: right;">Page 249</p> <p>1 Q. But that's not what this says. This says,</p> <p>2 "Jordan to have more oversight on patents." And</p> <p>3 you're referring to the Spanish patents here</p> <p>4 listed on Number 15, correct?</p> <p>5 A. No. This is an action item for the whole</p> <p>6 Section 15 above and below. So he was going to</p> <p>7 look at the Spanish patents as well.</p> <p>8 Q. Okay. And Jordan is going to visit Spain the</p> <p>9 week the 6th of January, correct?</p> <p>10 A. Yes.</p> <p>11 Q. And Jordan is going to call and coordinate that;</p> <p>12 is that correct?</p> <p>13 A. Yes.</p> <p>14 Q. And we saw an exhibit earlier with your personal</p> <p>15 handwritten notes that had about five items. I</p> <p>16 apologize. It's this document. I don't know --</p> <p>17 it was the undated document?</p> <p>18 MR. STEWART: What exhibit?</p> <p>19 MR. BOSTWICK: I don't have the</p> <p>exhibit number on it.</p> <p>21 MR. STEWART: What does it look like?</p> <p>22 What's the Bentley Bates number?</p> <p>23 MR. BOSTWICK: 1227. Is that it?</p> <p>24 MR. STEWART: Yes.</p>

<p style="text-align: right;">Page 250</p> <p>1 MR. BOSTWICK: What's the exhibit 2 number?</p> <p>3 MR. STEWART: 43.</p> <p>4 Q. If you could take a look at Exhibit 43 again. 5 Now, is this -- is the list of patents on 6 Bentley 1228 essentially the same as the list of 7 patents in the Bentley project status report on 8 November 20th, 2001, 15a through e?</p> <p>9 A. Yes.</p> <p>10 Q. So that's a Bentley project, correct?</p> <p>11 A. What's a Bentley project?</p> <p>12 Q. This list of items.</p> <p>13 A. This list of items here, these are patents from 14 Spain filed by the Spanish company, for which we 15 are taking a look at all of our intellectual -- 16 Bentley's intellectual property and that of its 17 subsidiaries.</p> <p>18 Q. Okay. In -- well, let me show it to you in this 19 manner.</p> <p>20 (Diary Entry was marked Exhibit Number 21 51 for identification.)</p> <p>22 MR. STEWART: Can we have a date for 23 Exhibit 51?</p> <p>24 MR. BOSTWICK: It says for</p>	<p style="text-align: right;">Page 252</p> <p>1 meeting, these list of people?</p> <p>2 A. Probably wanted to get out of the cold weather, 3 get into warm Florida weather. Other than that, 4 there's no recollection of why.</p> <p>5 Q. Did Adolfo Herrera come over to the U.S. 6 sometime around the end of 2001 or the beginning 7 of 2002?</p> <p>8 A. I don't know. I don't know.</p> <p>9 Q. I show you this.</p> <p>10 MR. STEWART: I'd going to need to 11 make my call.</p> <p>12 MR. BOSTWICK: You want to do that 13 before we --</p> <p>14 MR. STEWART: I think I ought to do 15 that.</p> <p>16 THE VIDEOGRAPHER: The time is 6 p.m. 17 We're going off the record.</p> <p>18 (Recess)</p> <p>19 THE VIDEOGRAPHER: The time is 20 6:07 p.m. We're back on the record. (Contrato de Transferencia de 22 Tecnología y Cesión de Know How and 23 Translation was marked Exhibit Number 52 for identification.)</p>
<p style="text-align: right;">Page 251</p> <p>1 December 4th, 2001. Maybe the witness can tell 2 us if that's when it was created or whether 3 that's a planning item for December 4th? 4 MR. STEWART: I want to go off the 5 record for just a minute, please. 6 THE VIDEOGRAPHER: Stand by. The time 7 is 5:57 p.m. We're going off the record. 8 (Recess) 9 THE VIDEOGRAPHER: The time is 10 5:58 p.m. We're back on the record. 11 Q. My question to you about this current 12 document -- what is it, 51? 13 A. 51. 14 Q. -- yeah -- is whether there was a Spanish 15 meeting in Florida sometime around December of 16 2001. 17 A. No, there was not. 18 Q. Okay. Was there a plan to do that and then it 19 didn't occur? 20 A. This, I believe, was notes to myself saying, 21 "Hey, it might be nice to get everybody together 22 for a meeting." It never happened. 23 Q. Why did you think it would be nice around 24 December of 2001 to get everybody together for a</p>	<p style="text-align: right;">Page 253</p> <p>1 Q. Mr. Murphy, I'm going to show you an Exhibit 52, 2 which is in Spanish. You and Mr. Price have 3 signed this document. I've provided a rough 4 translation here for your review in English. 5 After you've had a chance to look at that for a 6 minute, I'd like to know if you recognize that 7 document.</p> <p>8 A. Okay.</p> <p>9 Q. Do you recognize this document?</p> <p>10 A. No, I don't recognize it.</p> <p>11 Q. Now, this is a January 1st, 2002 transfer of 12 technology and assignment of know-how agreement. 13 Is that correct?</p> <p>14 A. Yes.</p> <p>15 Q. And it's signed by you on behalf of Laboratorios 16 Belmac as the sociedad unipersonal, correct?</p> <p>17 A. Yes.</p> <p>18 Q. And Mike Price on behalf of Bentley, correct?</p> <p>19 A. Yes.</p> <p>20 Q. What does sociedad unipersonal mean? Do you 21 know?</p> <p>22 MR. STEWART: Are you asking him to 23 translate the Spanish?</p> <p>24 MR. BOSTWICK: I'm asking if it's a</p>

<p style="text-align: right;">Page 254</p> <p>1 title, what it means.</p> <p>2 A. I do not know.</p> <p>3 MR. STEWART: Is there some -- are you</p> <p>4 testing out the translation that you have</p> <p>5 provided in the English translation? Is there</p> <p>6 an assertion that the translation that you</p> <p>7 provided is not accurate? Is that why you're</p> <p>8 asking him that question?</p> <p>9 MR. BOSTWICK: No, that's a specific</p> <p>10 title in Spanish, and I'm asking him since he</p> <p>11 signed under it whether he knows what that title</p> <p>12 means, not necessarily the translation of it,</p> <p>13 but what the title means; just like if it says</p> <p>14 CEO, what does that mean.</p> <p>15 Q. But do you know what that term "sociedad</p> <p>16 unipersonal" means?</p> <p>17 A. I do not know.</p> <p>18 Q. I take it from your prior testimony you don't</p> <p>19 recall signing this document. Is that the case?</p> <p>20 A. I don't recall, but I did sign this.</p> <p>21 Q. Okay. Is this a document of some importance to</p> <p>22 Bentley and Belmac?</p> <p>23 A. I believe that this probably has to do with tax</p> <p>24 planning again, with being able to document</p>	<p style="text-align: right;">Page 256</p> <p>1 Q. And how much does Bentley Pharmaceuticals</p> <p>2 receive for that purpose?</p> <p>3 A. I don't know that exact amount.</p> <p>4 Q. Does it say under Item 4 here of your translated</p> <p>5 version? Does it sound right to you that</p> <p>6 Laboratorios Belmac pays Bentley Pharmaceuticals</p> <p>7 500,000 euros per year?</p> <p>8 A. I don't know the exact amount. The accounting</p> <p>9 department would know.</p> <p>10 Q. And that amounts -- \$500,000 a year is</p> <p>11 approximately -- euros is approximately</p> <p>12 \$600,000?</p> <p>13 MR. STEWART: Objection.</p> <p>14 Q. Strike that. I need to ask that question again.</p> <p>15 500,000 euros is approximately \$600,000, is that</p> <p>16 correct?</p> <p>17 MR. STEWART: Objection.</p> <p>18 A. I don't know what the current exchange rate is.</p> <p>19 Q. Was Adolfo Herrera consulted with respect to</p> <p>20 this transfer of technology and assignment of</p> <p>21 know-how agreement?</p> <p>22 A. I don't know. I would think he would be.</p> <p>23 Q. Can you recall specifically sitting down with</p> <p>24 Mr. Herrera and discussing this agreement with</p>
<p style="text-align: right;">Page 255</p> <p>1 services that Bentley would provide to</p> <p>2 Laboratorios Belmac to justify management</p> <p>3 services fees and the distribution of overheads</p> <p>4 there.</p> <p>5 Q. Okay. So basically, do I understand that</p> <p>6 Belmac -- Laboratorios Belmac is going to pay</p> <p>7 Bentley Pharmaceuticals a management fee of</p> <p>8 sorts through this agreement?</p> <p>9 A. Bentley Pharmaceuticals receives management fees</p> <p>10 from Laboratorios Belmac.</p> <p>11 Q. For managing --</p> <p>12 A. For various services. Wherever it can be of</p> <p>13 service.</p> <p>14 Q. Okay. In other words, Laboratorios Belmac</p> <p>15 receives fees for managing Laboratorios Belmac?</p> <p>16 MR. STEWART: Objection. You said</p> <p>17 Laboratorios Belmac receives fees for managing</p> <p>18 Laboratorios Belmac.</p> <p>19 MR. BOSTWICK: My mistake. Thank you.</p> <p>20 Q. Bentley Pharmaceuticals receives management fees</p> <p>21 or fees for managing Laboratorios Belmac; is</p> <p>22 that correct?</p> <p>23 A. No, for providing services to Laboratorios</p> <p>24 Belmac.</p>	<p style="text-align: right;">Page 257</p> <p>1 him?</p> <p>2 A. I don't recall that. I believe it may have been</p> <p>3 Mike Price that may have talked to Adolfo</p> <p>4 because this is an accounting issue.</p> <p>5 Q. Who prepared this document? Was it people in</p> <p>6 the United States in your accounting group or</p> <p>7 your tax group or was it people in Spain?</p> <p>8 A. It was in Spanish, so it would probably not be</p> <p>9 prepared by the U.S. personnel.</p> <p>10 Q. Is this something Jordan Horvath was involved</p> <p>11 with?</p> <p>12 A. I don't think so.</p> <p>13 Q. Does the transfer of technology and the</p> <p>14 assignment of know-how in this arrangement go</p> <p>15 from Bentley to Laboratorios Belmac or to</p> <p>16 Laboratorios Belmac to Bentley (sic)?</p> <p>17 A. I'm not sure which direction this would be going</p> <p>18 in. Bentley Pharmaceuticals is technology in</p> <p>19 topical and transdermal, such as our topical</p> <p>20 testosterone gel.</p> <p>21 Q. I'm sorry. Where are you reading?</p> <p>22 A. I'm just telling you. So our personnel -- if we</p> <p>23 were to transfer any of our products into Spain</p> <p>24 for commercialization, our personnel would have</p>

65 (Pages 254 to 257)

<p style="text-align: right;">Page 258</p> <p>1 to go over there and train Laboratorios Belmac. 2 Q. In transdermal? 3 A. Uh-huh. 4 Q. Is -- have you sent people over from Bentley to 5 work on transdermal issues? 6 A. Yes. 7 Q. How many? 8 A. Three or four people. 9 Q. Okay. During what time period? 10 A. I don't know the exact time period, but it was 11 for intranasal insulin and for other drug 12 delivery-based products from the U.S. 13 Q. And how much time have those three to four 14 people from Bentley spent in Spain on that 15 issue? 16 A. I'm not sure the amount of time, but they would 17 go for weeks at a time. 18 Q. In the aggregate, how much time in a year? 19 A. I don't know. 20 Q. A month? 21 A. If you have three or four people and they spend 22 approximately a week or a week, then that almost 23 adds up to a month. It might even be more. 24 Q. And so your best estimate sitting here now is</p>	<p style="text-align: right;">Page 260</p> <p>1 Q. Well, you are CEO of Bentley and you're the 2 president of Belmac. Can you help me understand 3 why Laboratorios Belmac is paying Bentley 4 Pharmaceuticals 500,000 euros a year under this 5 agreement that you signed with Mr. Price? 6 A. No, I can't answer it. 7 Q. Who would know the answer to that question? 8 A. Mr. Price and the accounting department in 9 Spain.</p> <p>10 (Copy of E-mail to Mr. Murphy from 11 Ms. Sanchez, dated January 3, 2002 was 12 marked Exhibit Number 53 for 13 identification.)</p> <p>14 Q. Let me show you this e-mail. It's dated, I 15 believe, the 3rd of January, 2002, but my 16 Spanish isn't too good. The date's in Spanish. 17 A. Yes. 18 Q. Okay. So two days after this technology and 19 know-how agreement, there's an e-mail from you 20 to Concha Sanchez, correct? 21 A. Yes. 22 Q. And Concha Sanchez is a secretary for Adolfo 23 Herrera; is that correct? 24 A. Yes.</p>
<p style="text-align: right;">Page 259</p> <p>1 that every year three or four people spend an 2 average of about a month at Laboratorios Belmac 3 helping them with transdermal issues?</p> <p>4 MR. STEWART: Objection --</p> <p>5 A. No.</p> <p>6 MR. STEWART: -- mischaracterization 7 of testimony.</p> <p>8 Q. What is your best estimate?</p> <p>9 A. It's on occasion, and I don't know. It's on 10 occasion. It's not each and every year or 11 looking way back into the past, no.</p> <p>12 Q. Who are the three or four people who go over and 13 do this for Bentley?</p> <p>14 A. Eva Valasco, a technician, possibly Carl, 15 another technician in the laboratory, Bob Gyurik 16 would be the primary individuals.</p> <p>17 Q. And for this, Bentley receives half a million 18 euros a year?</p> <p>19 A. That's an example I gave you. I'm not saying 20 that all that alone is equal to the half 21 million. I do not know.</p> <p>22 Q. What else does Bentley do for Laboratorios 23 Belmac to make this money?</p> <p>24 A. I don't know.</p>	<p style="text-align: right;">Page 261</p> <p>1 Q. At Laboratorios Belmac?</p> <p>2 A. Yes.</p> <p>3 Q. And you have indicated that you want to remind 4 Adolfo to send the complete omeprazole dossiers 5 for filing in the U.S.A.; is that correct?</p> <p>6 A. For review to see if it would be compliant or 7 capable of being filed in the U.S.</p> <p>8 Q. So one of the benefits that Bentley is getting 9 from Laboratorios Belmac is the omeprazole 10 dossiers and you're going to file for generics 11 in the U.S.; is that correct?</p> <p>12 A. It was being explored we wanted to look into 13 doing that.</p> <p>14 Q. Were those dossiers of omeprazole sent to you?</p> <p>15 A. Yes.</p> <p>16 Q. And did you file -- make generic filings in the 17 U.S.?</p> <p>18 A. No.</p> <p>19 Q. Okay. What -- why not?</p> <p>20 A. The dossiers were not, in our opinion, to the 21 standards for filing in the U.S., and the U.S. 22 would require additional clinical studies.</p> <p>23 Q. So they weren't sufficient?</p> <p>24 A. We didn't feel they were sufficient for the U.S.</p>

66 (Pages 258 to 261)

<p style="text-align: right;">Page 262</p> <p>1 Q. Is Bentley currently taking those dossiers, 2 building on them in an effort to file 3 generically in the U.S.?</p> <p>4 A. We could. That decision has not been made.</p> <p>5 Q. There's no plans internally to do that today?</p> <p>6 A. We're looking at it. It's pretty late to file 7 on omeprazole in the U.S. There's a lot of them 8 out there already.</p> <p>9 Q. How about lansoprazole? Did the dossiers for 10 lansoprazole come over to the U.S. as well?</p> <p>11 A. Not to my recollection.</p> <p>12 Q. Have you made generic filings for lansoprazole 13 here in the U.S.?</p> <p>14 A. No.</p> <p>15 Q. Is that under exploration currently?</p> <p>16 A. It's being considered.</p> <p>(Copy of E-mail to Mr. Bolling, et al. from Mr. Fitzgibbons, dated January 22, 2002, and Attachment were marked Exhibit Number 54 for identification.)</p> <p>21 Q. I'm showing you Exhibit 54, and I'd ask you to 22 confirm that that's an operations update, 23 January 22nd, 2002, of Bentley Pharmaceuticals, 24 Inc.</p>	<p style="text-align: right;">Page 264</p> <p>1 Belmac?</p> <p>2 MR. STEWART: Objection. He just 3 answered the question. Asked and answered.</p> <p>4 A. Some of them have contacted us, worried about 5 supply of omeprazole and wanted to discuss 6 recontracting with us.</p> <p>7 Q. And, in fact, we saw PharmAlliance on 8 November 14th, 2001 had already entered into a 9 confidentiality agreement; is that correct?</p> <p>10 A. I saw it. You showed it to me here.</p> <p>11 Q. And this is all happening before the formal 12 termination, not the notice of termination, but 13 before the termination of the contract between 14 Ethypharm and Belmac, correct?</p> <p>15 A. Yes.</p> <p>16 MR. BOSTWICK: Okay. I don't have any 17 further questions at this time. I may if we 18 have some more questions for Mr. Murphy.</p> <p>19 MR. STEWART: I'll need about five, 20 five minutes or so to pull together my papers 21 for the hour and a half of questions that I 22 have.</p> <p>23 THE VIDEOGRAPHER: The time is 6:28.</p> <p>24 MR. BOSTWICK: You have an hour and a</p>
<p style="text-align: right;">Page 263</p> <p>1 A. Yes.</p> <p>2 Q. And it's got a cover letter or -- a cover e-mail 3 on the front, and you're one of the recipients; 4 is that correct?</p> <p>5 A. Yes.</p> <p>6 Q. All right. And under the Bentley 7 Pharmaceuticals Operations Update, the Spain 8 Activities, 1 A, is "filed for new patents for 9 improved orally delivered products, including 10 omeprazole and lansoprazole. Press release 11 issued November 14th, 2001." Correct?</p> <p>12 A. Yes.</p> <p>13 Q. And under E, it says, "Ethypharm's customers for 14 omeprazole in process of re-contracting with 15 Laboratorios Belmac." Correct?</p> <p>16 A. Yes.</p> <p>17 Q. And is that true, that was happening on 18 January 22nd, 2001?</p> <p>19 A. I believe their customers had contacted us with 20 concerns about where they were going to get 21 their supply.</p> <p>22 Q. Is this a true statement, that in January 22nd, 23 2002, Ethypharm customers for omeprazole in 24 process of re-contracting with Laboratorios</p>	<p style="text-align: right;">Page 265</p> <p>1 half of questions? Okay.</p> <p>2 THE VIDEOGRAPHER: The time is 3 6:28 p.m. We're going off the record.</p> <p>4 (Recess)</p> <p>5 THE VIDEOGRAPHER: The time is 6 6:42 p.m. We're back on the record.</p> <p>7 MR. STEWART: On the record?</p> <p>8 MR. BOSTWICK: Sure.</p> <p>9 EXAMINATION BY MR. STEWART:</p> <p>10 Q. Mr. Murphy, as you know, I'm Craig Stewart, and 11 I represent Bentley Pharmaceuticals in this 12 matter. I have really relatively few questions 13 to ask of you at this time, but just a few 14 things to touch up some points that Mr. Bostwick 15 raised.</p> <p>16 Would you turn to Exhibit 52 for a 17 moment, please? This is the so-called Transfer 18 of Technology and Assignment of Know-how 19 Agreement.</p> <p>20 A. Yes.</p> <p>21 Q. Did you have anything to do with the preparation 22 of this document?</p> <p>23 A. No.</p> <p>24 Q. Is it your understanding that Laboratorios</p>

67 (Pages 262 to 265)

<p style="text-align: right;">Page 266</p> <p>1 Belmac has employees -- has its own employees? 2 A. Yes. 3 Q. Approximately how many employees? 4 A. Approximately 350. 5 Q. Does it have manufacturing facilities? 6 A. Yes. 7 Q. Does it have technology? 8 A. Yes. 9 Q. Does it have patents? 10 A. Yes. 11 Q. Does it have a need for services pertaining to 12 its operations in Spain? 13 A. With regard to manufacturing? With regard to 14 development or -- 15 Q. Any services, especially with respect to such 16 overhead services as accounting. 17 A. Yes, it needs services such as reporting 18 services for SEC reporting and the conversion of 19 their statutory accounts to U.S. GAAP and such. 20 Q. Now, Exhibit 52 you told us to your 21 understanding was drafted for -- it was prepared 22 at least in part for tax purposes. 23 A. Yes. 24 Q. Is that your testimony?</p>	<p style="text-align: right;">Page 268</p> <p>1 different projects with different universities, 2 with different discussions for potential 3 licensing or acquisition of products or it could 4 be anything. It's to help me keep my fingers on 5 the operation. 6 Q. You say keep your fingers on the operation. 7 Does that mean keep your fingers on the 8 operation of -- do you mean so that you can 9 manage? 10 MR. BOSTWICK: Objection, leading. 11 A. Just so I can be updated as to the status of 12 everything and be aware of it and essentially 13 answer questions to the board of directors as 14 well. 15 Q. If you turn to the Section 15, New Patents? 16 A. Yes. 17 Q. And Mr. Bostwick asked you some questions about 18 that section, in particular, on the action item, 19 "Jordan and Bob G. to review patent issues, 20 Jordan to have more oversight on patents." Do 21 you see that? 22 A. Yes. 23 Q. Now, you've told us that the Jordan in question 24 is a Jordan Horvath; is that right?</p>
<p style="text-align: right;">Page 267</p> <p>1 A. Yes. 2 Q. Do you know what were the tax benefits that 3 would accrue to either Belmac or Bentley as a 4 result of this document? 5 A. Yes. 6 Q. In general, what were they? 7 A. Laboratorios Belmac can account for a reasonable 8 amount of management fees paid to a parent 9 company, and by paying those fees, then they 10 would save the taxes. The tax rate is at 11 35 percent in Spain. So any reasonable fee that 12 would be allowed in management services fees or 13 any other fees would save them quite a bit of 14 money in taxes. 15 Q. Turn, if you would, to Exhibit 50. 16 A. Yes. 17 Q. And in particular, turn to Page 3 of Exhibit -- 18 of the document that is titled Project and 19 Status. Do you have it? 20 A. Yes. 21 Q. First, what is the -- what's the purpose of the 22 project and status report? 23 A. This is just primarily to keep me up to date, 24 help me be organized because there's so many</p>	<p style="text-align: right;">Page 269</p> <p>1 A. Jordan Horvath. 2 Q. And at the time, he was in-house counsel for 3 Bentley Pharmaceuticals? 4 A. Yes. 5 Q. What was the oversight that Mr. Horvath was to 6 have? What was he to do? 7 A. He was to keep me abreast of the status of all 8 patents, to make sure that if we were filing in 9 Europe that he was able to coordinate with U.S. 10 patent attorneys to make sure that no territory 11 in the U.S. or any other part of the world fell 12 through the cracks, and it was really to protect 13 the library of patents under the whole Bentley 14 umbrella. 15 Q. Did Mr. Horvath have anything to do with respect 16 to the patents that are listed under Patent 17 Spain, first, second, third, fourth, and fifth 18 patent? 19 A. No, nothing, other than just to report to me on 20 the status and follow up to make sure that all 21 of the different territories were filed. 22 Q. Who was responsible for actually doing the work 23 to draft and file the patents that I've just 24 mentioned, 1, 2, 3, 4, and 5?</p>

<p style="text-align: right;">Page 270</p> <p>1 A. Laboratorios Belmac.</p> <p>2 Q. Turn, if you would, to Exhibit 37. It's a</p> <p>3 document should be called Operations Update.</p> <p>4 A. Yes.</p> <p>5 Q. What is an operations -- what is the</p> <p>6 operations -- as of 2001, what was the</p> <p>7 operations update?</p> <p>8 MR. BOSTWICK: Objection, asked and</p> <p>9 answered.</p> <p>10 A. The operations update was a summary provided by</p> <p>11 Paul Fitzgibbons of all different activities</p> <p>12 throughout Bentley and Laboratorios Belmac, and</p> <p>13 it was provided to the board of directors, who</p> <p>14 felt they would like to have more frequent</p> <p>15 reports than our quarterly meetings.</p> <p>16 Q. And how does that differ from the project status</p> <p>17 report that we spoke about a couple of moments</p> <p>18 ago?</p> <p>19 A. At Paul's discretion, he would take just</p> <p>20 highlights to keep them up to date.</p> <p>21 Q. These were highlights from the project status</p> <p>22 reports?</p> <p>23 A. Yes.</p> <p>24 Q. And under Point 1, Spain Activities, little E,</p>	<p style="text-align: right;">Page 272</p> <p>1 drugs utilizing Bentley technology from the</p> <p>2 United States.</p> <p>3 Q. And who were you talking about that stuff with?</p> <p>4 A. I was talking to Ethypharm, Ethypharm France.</p> <p>5 Q. And during what period were you talking about</p> <p>6 enhancement of absorption and permeation of</p> <p>7 drugs through biological membranes with</p> <p>8 Ethypharm?</p> <p>9 A. Oh, I talked to them over a number of years,</p> <p>10 stretching way back at various times.</p> <p>11 Q. All right. And the date of the confidentiality</p> <p>12 and nondisclosure agreement?</p> <p>13 A. Yes, this was February 2000.</p> <p>14 Q. And I think Mr. Bostwick pointed out that the</p> <p>15 actual signing date of this is April 2000. Is</p> <p>16 that right?</p> <p>17 A. Yes.</p> <p>18 Q. Now, do you know whether the discussions</p> <p>19 proceeded with Ethypharm with respect to this</p> <p>20 topic during 2000 and up to, say, 2001?</p> <p>21 A. I believe that they did.</p> <p>22 Q. Showing you or calling your attention to</p> <p>23 Exhibit 37, "Ethypharm, negotiations terminated</p> <p>24 due to lack of full commitment from Ethypharm."</p>
<p style="text-align: right;">Page 271</p> <p>1 Ethypharm, Mr. Bostwick asked you some questions</p> <p>2 about that item; did he not?</p> <p>3 A. Yes.</p> <p>4 Q. And item e says, "Ethypharm - negotiations</p> <p>5 terminated due to lack of full commitment from</p> <p>6 Ethypharm." Have I read that correctly?</p> <p>7 A. Yes.</p> <p>8 Q. Now, you told Mr. Bostwick that you weren't sure</p> <p>9 what that referred to; is that right?</p> <p>10 A. Right.</p> <p>11 Q. Mr. Bostwick asked you whether that referred to</p> <p>12 the decision which was made -- ultimately made</p> <p>13 not to renew the manufacturing agreement, right?</p> <p>14 A. Yes.</p> <p>15 Q. Turn, if you would, to Exhibit 8. Exhibit 8 is</p> <p>16 at the end.</p> <p>17 A. Yes.</p> <p>18 Q. And Mr. Bostwick showed you Exhibit 8. Can you</p> <p>19 tell us what Exhibit 8 is?</p> <p>20 A. It's a confidentiality and nondisclosure</p> <p>21 agreement.</p> <p>22 Q. For what purpose?</p> <p>23 A. So that I could talk drug delivery systems and</p> <p>24 enhancement of the permeation and absorption of</p>	<p style="text-align: right;">Page 273</p> <p>1 Could this be the negotiations that were</p> <p>2 referenced in this document, Exhibit 37?</p> <p>3 A. It could be.</p> <p>4 Q. Then, if you would turn, please, to Exhibit 31,</p> <p>5 the manufacturing agreement.</p> <p>6 A. Yes.</p> <p>7 Q. Did you participate -- would you remind us what</p> <p>8 Exhibit 31 is, please?</p> <p>9 A. Have to see the English translation. It's a</p> <p>10 manufacturing contract.</p> <p>11 Q. And who was the manufacturing contract between?</p> <p>12 A. Between Laboratorios Belmac and Laboratorios</p> <p>13 Ethypharm Spain.</p> <p>14 Q. And who was it signed by on behalf of</p> <p>15 Laboratorios Belmac?</p> <p>16 A. Adolfo Herrera.</p> <p>17 Q. And for Laboratorios Ethypharm S.A.?</p> <p>18 A. It appears that would be Adolfo Basilio, but I'm</p> <p>19 not sure if I recognize that.</p> <p>20 Q. Did you direct -- first, let me ask. Did you --</p> <p>21 were you involved in the drafting of the</p> <p>22 manufacturing contract between Laboratorios</p> <p>23 Ethypharm and Laboratorios Belmac?</p> <p>24 A. No.</p>

69 (Pages 270 to 273)

<p style="text-align: right;">Page 274</p> <p>1 Q. Who drafted the agreement between Laboratorios 2 Belmac and Laboratorios Ethypharm?</p> <p>3 A. I believe it was probably Adolfo and Adolfo 4 Basilio.</p> <p>5 Q. Did Bentley Pharmaceuticals have anything to do 6 with the preparation of this agreement?</p> <p>7 A. No.</p> <p>8 Q. Did you direct Adolfo Herrera to draft the 9 manufacturing agreement?</p> <p>10 A. No.</p> <p>11 Q. And showing you or -- directing your attention 12 to Paragraph G of the manufacturing agreement, 13 what is required notice for either party to 14 cancel the agreement?</p> <p>15 A. Four months.</p> <p>16 Q. And turn, please, if you would, to Exhibit 39.</p> <p>17 A. Yes.</p> <p>18 Q. And Exhibit 39, I believe you told us, is from 19 your business journal that you kept during this 20 time?</p> <p>21 A. Yes.</p> <p>22 Q. And referring to the entry dated 5-23-01, I 23 believe it was your testimony that this was your 24 own internal tickler of things to think about;</p>	<p style="text-align: right;">Page 276</p> <p>1 Q. It's your testimony that Adolfo Herrera advised 2 you that that would be his intention; is that 3 correct?</p> <p>4 A. Yes.</p> <p>5 Q. And it -- does it remain your testimony that 6 Mr. Herrera made that decision?</p> <p>7 A. Yes.</p> <p>8 Q. Did you at any time either explicitly or 9 implicitly direct Mr. Herrera to give notice of 10 nonrenewal of the manufacturing agreement?</p> <p>11 A. No.</p> <p>12 Q. Did you -- was there anything wrong with -- in 13 your judgment, with regard to Mr. Herrera of 14 giving notice of nonrenewal of the manufacturing 15 agreement?</p> <p>16 A. Not -- I don't think so and I don't know.</p> <p>17 Q. Now, who were the -- to your knowledge, who were 18 the owners of Ethypharm France?</p> <p>19 A. I believe it was a partnership of Mr. Leduc and 20 Mr. DeBregeas.</p> <p>21 Q. And from time to time, you had discussions with 22 Mr. Leduc and Mr. DeBregeas?</p> <p>23 A. Yes.</p> <p>24 Q. At any time, did you ever tell Mr. Leduc or</p>
<p style="text-align: right;">Page 275</p> <p>1 is that right?</p> <p>2 A. This could be or it could be relayed to me by 3 Mike Price.</p> <p>4 Q. I'm going to direct your attention to Item 4, 5 "Ethypharm expire May 2002, six-month notice 6 required, September." Do you see that?</p> <p>7 A. Yes.</p> <p>8 Q. And you wrote that, right?</p> <p>9 A. Yes.</p> <p>10 Q. Did you know at the time how many months was 11 required to provide notice in order to terminate 12 the March of -- March 23, 2000 manufacturing 13 agreement?</p> <p>14 A. Apparently not. I was wrong, six months.</p> <p>15 Q. And referring, please, to Exhibit 34. Is it 16 your -- now, you've -- tell us what Exhibit 34 17 is, please.</p> <p>18 A. Exhibit 34, as translated here, it appears to 19 be -- it is the -- giving notice.</p> <p>20 Q. I'm sorry?</p> <p>21 A. Communicating our decision to cancel the 22 manufacturing contract.</p> <p>23 Q. And did you see this letter before it was sent?</p> <p>24 A. No, I did not.</p>	<p style="text-align: right;">Page 277</p> <p>1 Mr. DeBregeas that any agreement made by 2 Laboratorios Belmac was -- should be considered 3 as an agreement by Bentley Pharmaceuticals, 4 Incorporated?</p> <p>5 A. No.</p> <p>6 Q. Do you have any reason to believe that either 7 Mr. Leduc or Mr. DeBregeas were aware you were 8 president of Laboratorios Belmac?</p> <p>9 A. I believe they both knew I was president of 10 Laboratorios Belmac.</p> <p>11 Q. And how would they have known that?</p> <p>12 A. Because routinely when I'm traveling in Europe, 13 I hand two cards out; one which is Laboratorios 14 Belmac, indicating me as president, and another 15 for the parent company in the United States, 16 Bentley.</p> <p>17 Q. Are you aware of any draft agreements in which 18 you are named as executive director of 19 Laboratorios Belmac?</p> <p>20 A. Yes, I believe there was some where I was called 21 executive director of Laboratorios Belmac.</p> <p>22 Q. And at any time, did you tell Mr. Leduc or 23 Mr. DeBregeas that actions taken by Laboratorios Belmac should be -- would be actions that they</p>

70 (Pages 274 to 277)

<p>1 should consider to be taken by Bentley. 2 Pharmaceuticals? 3 A. No. 4 Q. Did you ever tell Mr. Leduc, Mr. DeBreges or 5 anyone else at Ethypharm that Laboratorios 6 Belmac had authority to act on behalf of Bentley 7 Pharmaceuticals, Incorporated? 8 A. No. 9 Q. Did you ever tell Mr. Leduc, Mr. DeBreges or 10 anyone else at Bentley that they should consider 11 any action that you took on behalf of 12 Laboratorios Belmac to bind Bentley 13 Pharmaceuticals, Incorporated? 14 A. No. 15 MR. STEWART: I have nothing further. 16 MR. BOSTWICK: Okay. Just a couple of 17 questions on Mr. Stewart's last point. 18 RE-EXAMINATION BY MR. BOSTWICK: 19 Q. Can you refer to Exhibit 1, Paragraph 24? 20 A. Yes. 21 Q. This paragraph, why don't I give you a moment to 22 read it over, just the Paragraph 24. 23 A. Uh-huh. 24 Yes.</p>	<p>Page 278</p> <p>1 to intercede because they had a communication 2 problem with Belmac, they knew I was coming as 3 president of Belmac to try to solve that 4 problem. The distinction was pretty easy to 5 see, and they both -- they all knew of my 6 capacity in the two different companies. 7 Q. Okay. Well, I can understand how they might 8 think you're representing both companies at all 9 times, but how is it that they would understand 10 that you're taking off your Bentley hat, you're 11 not acting for Bentley at all, and you're only 12 acting as Laboratorios Belmac in any specific 13 discussion? 14 A. By the context of our discussion. 15 Q. Can you give me -- let's talk about, for 16 example, the 1995 meetings when you come over to 17 talk to Mr. DeBreges in Paris and Adolfo de 18 Basilio, and you introduce yourself, your role 19 at Bentley, your role at Belmac. Can you give 20 me a specific factual example of what you did to 21 clarify when you were acting only in the 22 capacity as Laboratorios Belmac? 23 A. I can't think of any specific one in 1995. 24 Q. How about your meeting with Claude Dubois in</p>
<p>1 Q. In this paragraph, you indicate when you 2 directly interacted with Ethypharm, it has been 3 in two different contexts. Do you see that? 4 A. Yes. 5 Q. And the first contact you talk about is as in 6 the capacity of president of Belmac, and you 7 say, "To the extent I participated in these 8 issues, it was solely in my capacity as an 9 officer of Belmac and not on behalf of Bentley," 10 correct? 11 A. Yes. 12 Q. Now, you said you think you may have given two 13 cards out to some of the individuals at 14 Ethypharm, correct? 15 A. Yes. 16 Q. What specific steps did you take to indicate to 17 people at Ethypharm when you were solely acting 18 as your capacity as an officer of Belmac and not 19 Bentley? 20 A. When we had discussions, I would say, "In 21 Bentley or in the States, we have drug delivery 22 activities. Do you have an interest in 23 products, these potential applications?" Or if 24 I was responding to them at their request to try</p>	<p>Page 279</p> <p>1 1997? Can you think of a specific example of 2 something you said or did to Mr. Dubois that 3 would clarify for him that at a certain point in 4 that discussion you had taken off your Bentley 5 hat and you were only talking to him as 6 Laboratorios Belmac? 7 A. I think you can see that in his summary of his 8 memo, which I don't have handy here, but he made 9 the distinction. 10 Q. Okay. Well, not referring to his memo, but just 11 your memory and your understanding. Can you 12 give me a specific action that you took, a 13 statement that you made or something that you 14 did that would clarify for Mr. Dubois that there 15 was a moment in time in the meeting where you 16 had taken off your Bentley hat and you were only 17 Laboratorios Belmac? 18 A. I can't think of a single thing within that 19 discussion. 20 Q. Okay. How about in any discussion that you ever 21 had with anyone at Ethypharm? Can you provide 22 me with a specific factual example of something 23 that you did to let the people at Ethypharm know 24 that there was a moment in time in that</p>

71 (Pages 278 to 281)

<p style="text-align: right;">Page 282</p> <p>1 discussion where you were not acting as Bentley 2 but you were only wearing one hat --</p> <p>3 A. Yes.</p> <p>4 Q. -- and it was a Laboratorios Belmac hat?</p> <p>5 A. Yes.</p> <p>6 Q. Okay. When was that?</p> <p>7 A. When we signed the confidential agreement to 8 discuss the permeation of new drugs and the 9 application of drug delivery systems.</p> <p>10 Q. Okay. That would be an example, if I'm 11 understanding you correct -- correctly, that 12 would be an example where you were saying, "I'm 13 only acting with my Bentley hat," correct?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. What I'm asking is when was there a time 16 when you can recall through your actions or a 17 specific statement you made that clarified for 18 the people at Ethypharm that you had taken off 19 your Bentley hat and you were only acting solely 20 in your capacity as an officer of Belmac and not 21 on behalf of Bentley?</p> <p>22 A. There were meetings we had in Paris where I 23 would come to try to, say, resolve problems they 24 were having in communication with Belmac, and</p>	<p style="text-align: right;">Page 284</p> <p>1 Q. And Mr. Bostwick asked you some questions about 2 Exhibit 40. And turn, if you would, to the 3 letter from Mr. Gerard Leduc, dated June 8, 4 2001. Do you have it?</p> <p>5 A. Yes:</p> <p>6 Q. And that letter is addressed to you; is that 7 right?</p> <p>8 A. Yes.</p> <p>9 Q. And who -- what is the company that it is 10 addressed to?</p> <p>11 A. On the top right here?</p> <p>12 Q. Yes.</p> <p>13 A. It's Bentley Pharmaceuticals, Inc.</p> <p>14 Q. And let me read to you the first sentence. 15 "Dear sir: Further to our discussion of the 16 beginning of year 2000, please find attached a 17 draft of agreement aiming at regularizing the 18 relationship between Ethypharm and Belmac." Do 19 you see that?</p> <p>20 A. Yes.</p> <p>21 Q. Who did you understand to be the Belmac that is 22 referred to in that sentence?</p> <p>23 A. Laboratorios Belmac.</p> <p>24 Q. And Mr. Leduc attached to this letter a draft</p>
<p style="text-align: right;">Page 283</p> <p>1 then we would go into other business and other 2 discussions of, "Oh, what do we want to do with 3 this stateside pharmaceutical products for 4 permeation enhancement?" We would talk about 5 the potential application of different products.</p> <p>6 Q. I understand you may have talked about different 7 topics, but how -- is there a specific statement 8 you made or something you did or said that would 9 let them know that at a certain moment you had 10 taken off your Bentley hat and you were 11 acting -- and I'm reading your affidavit -- 12 solely in your capacity as officer of Belmac and 13 not on behalf of Bentley?</p> <p>14 A. I can't think of anything specific.</p> <p>15 MR. BOSTWICK: I don't have anything 16 further.</p> <p>17 MR. STEWART: Just one last document.</p> <p>18 RE-EXAMINATION BY MR. STEWART:</p> <p>19 Q. Could you turn to Exhibit 40, please?</p> <p>20 A. These are out of order now.</p> <p>21 Q. If you want to pass over the top couple of 22 inches, I can see --</p> <p>23 A. I'm getting there. It's out of order. 42. Got 24 it.</p>	<p style="text-align: right;">Page 285</p> <p>1 agreement, correct?</p> <p>2 A. Yes.</p> <p>3 Q. Was this an agreement that you had anything to 4 do with?</p> <p>5 A. No.</p> <p>6 Q. This was an agreement that was prepared by 7 Ethypharm, correct?</p> <p>8 A. This was prepared by Ethypharm.</p> <p>9 Q. And turn, if you would, to the last page of the 10 agreement, Page 26.</p> <p>11 A. Yes.</p> <p>12 Q. And would you read for us, please, what is 13 written in the signature blocks, first for 14 Ethypharm and then for Belmac?</p> <p>15 A. For Ethypharm S.A., Mr. Patrice DeBregeas, 16 president.</p> <p>17 Q. And this was the space for Mr. DeBregeas to date 18 and sign?</p> <p>19 A. Yes.</p> <p>20 Q. For Ethypharm S.A.?</p> <p>21 A. Yes.</p> <p>22 Q. For now Belmac?</p> <p>23 A. For Belmac, S.A., Mr. James R. Murphy, executive 24 director.</p>

1 Q. And were you the executive director for Belmac,
2 S.A. at that time?
3 A. I was the executive director.
4 Q. For Laboratorios Belmac?
5 A. Yes.
6 Q. Mr. Murphy, are you aware of any signed
7 agreement between Ethypharm and Bentley
8 Pharmaceuticals, Incorporated with respect to
9 the manufacture of omeprazole or other
10 pharmaceutical products for Ethypharm S.A. or
11 involving any technology which relates to the
12 manufacture of omeprazole?
13 A. Between Bentley and Ethypharm, no.
14 MR. STEWART: I have nothing further.
15 MR. BOSTWICK: We can go on forever.
16 THE VIDEOGRAPHER: The time is
17 7:15 p.m. on July 19th, 206. This is the end of
18 Tape Number 4, and this completes the videotape
19 deposition of Mr. James Murphy.
20 (Deposition concluded at 7:15 p.m.)
21
22
23
24

1 CERTIFICATE
2
3 COMMONWEALTH OF MASSACHUSETTS
4 SUFFOLK, SS
5 I, Sandra L. Bray, Registered Diplomate
6 Reporter and Notary Public in and for the
7 Commonwealth of Massachusetts, do hereby
8 certify:
9 That JAMES R. MURPHY, the witness whose
10 deposition is hereinbefore set forth, was duly
11 sworn by me and that such deposition is a true
12 record of my stenotype notes taken in the
13 foregoing matter, to the best of my knowledge,
14 skill and ability.
15 IN WITNESS WHEREOF, I have hereunto set
16 my hand this 5th day of August, 2006.
17
18

19 Sandra L. Bray, RDR
20 Registered Diplomate Reporter
21
22
23
24

73 (Pages 286 to 288)

A	279:17 280:11 280:12,21 282:1 282:13,19 283:11	93:12 96:17 110:2,14 111:19 121:14 126:13 127:1,18,19	161:4,17 195:13 195:16 agreeing 127:7 agreement 3:20	6:16,23 125:4 205:12 234:9 247:9 262:17
able 42:5 43:9 199:15 214:3 288:14	action 5:17 43:8 164:2,16 195:3 195:13 198:9 201:12 202:13 203:5 204:9 231:12 248:4 249:5 268:18 278:11 281:12	149:9 156:20 175:18 186:12 186:12 187:1,2 189:3 194:22 195:20 197:3 203:16,17 204:12,13 208:20,21 212:9	4:6 5:24 6:15 71:1 75:8,13 76:7,16 86:3 91:3 94:9 101:10	alert 125:1 138:17 alerted 115:5 130:9 alerting 142:11,24 145:13 148:5 166:21 222:12
abreast 197:24 205:5 269:7	actions 31:15 222:13 277:23 277:24 282:16	212:10,13 217:7 217:10 219:21 222:7,12 229:22	120:12 121:1 124:7,12,15 142:4 148:1	allegedly 194:20 allow 43:9 allowed 20:5 195:10 197:3 267:12
absolutely 57:15 57:18,19 76:9	active 160:21 163:11	246:15 252:5 256:19 257:3	153:16,19,20,22 165:18 176:5,13	amended 86:17 amorphous 90:4 90:14
absorption 76:19 271:24 272:6	activities 58:17 64:19 99:18 115:9 167:20,20	260:22 261:4 273:16,18 274:3 274:3,8 276:1 280:17	187:15 190:19 191:8 192:12 194:18 212:21 213:4,5 214:11	amount 61:8 112:21,22,23 113:8 152:24 256:3,8 258:16 267:8
accept 41:18 43:1 60:22	Adolfo's 212:14	214:23 215:14	215:18 221:13	amounts 63:24 256:10
acceptable 247:4	adopt 176:7	221:16,18,20,21	221:22,23 222:2	analysis 193:21
access 41:20 43:3	adopted 47:6 50:9	222:4,9,10	222:4,9,10	analytical 141:14 210:13
accommodate 22:10	advantage 39:4	229:22 240:14	229:22 240:14	Angell 1:20 2:10 7:19
account 41:18 42:6,8,24 43:10 188:9,12 267:7	advised 276:1	245:16,21	245:16,21	announce 188:23 204:6,14,19,20 204:23 205:1,7
accounted 46:14	advisors 243:22	246:10,16	246:10,16	announced 240:24 241:6
accounting 48:19 49:11,12 50:15 50:17 256:8 257:4,6 260:8 266:16	affect 142:1	253:12 255:8	253:12 255:8	announcement 94:6,7 246:8
accounts 266:19	affidavit 14:16	256:21,24 260:5	256:21,24 260:5	annual 112:23
accrue 267:3	154:22 163:16	260:19 264:9	260:19 264:9	answer 9:7,9,20 29:7 42:2,3,4
accumulation 14:3	165:14 272:15	265:19 271:13	265:19 271:13	45:14 46:10,11 49:9,10 51:1
accurate 60:10 66:4 86:11,12,13 120:20,22,23 124:3 128:9 149:3 254:7 287:6	add 61:22 62:19	271:21 272:12	271:21 272:12	57:18 60:5 61:10 63:10 69:17 88:8
acknowledge 92:5	additional 96:9	273:5 274:1,6,9	273:5 274:1,6,9	ahead 20:2 92:12
acknowledging 173:16	171:10 183:19	274:12,14	274:12,14	aiming 284:17
acquire 183:18	186:19,20,23	275:13 276:10	275:13 276:10	airline 70:5
acquired 58:16	261:22	276:15 277:1,3	276:15 277:1,3	answered 32:15 43:5 57:17 64:22
acquisition 268:3	addressed 284:6	282:7 284:17	282:7 284:17	264:3,3 270:9
act 84:14 132:13 243:22 278:6	284:10	285:1,3,6,10	285:1,3,6,10	answering 38:16
acted 200:14	addressing 150:2	286:7	286:7	
acting 72:18 83:8 84:7,9,12 243:7	162:12	agreements 47:6	agreements 47:6	
	adds 258:23	74:17 92:3	74:17 92:3	
	adjustment 22:18	100:15 109:4	100:15 109:4	
	administer 183:22	120:16 147:17	120:16 147:17	
	Adolfo 19:12,16	174:7 176:4,19	174:7 176:4,19	
	19:17 20:14	177:5 192:12	177:5 192:12	
	26:23,24 27:1,4	216:2 277:17	216:2 277:17	
	28:15 33:10 34:8	ahead 20:2 92:12	ahead 20:2 92:12	
	34:17 54:24 55:3	aiming 284:17	aiming 284:17	
	55:11 57:10	airline 70:5	airline 70:5	
	77:21 79:21,22	84:16 5:19 6:12	84:16 5:19 6:12	
	80:21 89:1 91:15	answering 38:16	answering 38:16	

Page 290

169:5	28:4,6	264:3 268:17	attendance 42:19	268:12 277:7,17
answers 10:12	approximately	270:8 271:1,11	163:10	286:6
anticipation 11:20	7:13 24:19 25:19	284:1	attended 79:10	awful 160:2,5
93:16 209:24	26:2,7 36:2 40:4	asking 44:10 46:5	85:17 155:11	Ayala 17:17 87:17
anxious 81:15	44:1,15,20 46:13	98:6,9 99:22	157:24 230:24	88:19
anybody 106:8	48:8 51:13 61:2	103:8,14,14	attending 22:1	Azpetia 19:12
177:17 196:9	61:5,12 62:6,15	148:15 155:3	24:5	78:24 80:1
214:8	62:21 66:6 71:5	176:7 192:7	attention 22:7	Azpetia's 78:19
anybody's 238:7	73:21 199:2,9	202:23 233:20	24:8 25:6 34:15	a.m 1:23 7:13
anyway 174:22	256:11,11,15	237:20,24	36:20 37:4 67:6	36:20 37:4 67:6
183:24	258:22 266:3,4	253:22,24 254:8	67:9 92:16,21	67:9 92:16,21
apart 169:16	approximation	254:10 282:15	107:10	
API 160:21 209:22	60:24 61:2	aspect 141:10		B
210:1,3,6,13	April 75:17	147:2		B 3:6 4:1 5:1 6:1
apologize 37:17	110:22 111:17	aspects 68:3 200:9	12:21 64:22	
119:13 141:7	112:6,14 155:7	assertion 254:6	165:1	
249:16	155:24 156:14	assessing 199:21	BAACH 2:3	
apparently 55:6	158:5 160:12	200:3	back 18:23 21:5	
84:24 90:2 91:16	168:22 170:3,22	assignment	31:19 32:24 33:2	
131:23 139:17	171:3 173:10	253:12 256:20	37:4,12 50:11,13	
145:13 161:2,7	213:22 272:15	257:14 265:18	51:1 56:14,19	
171:14 214:19	aqueous 164:3,4,8	assist 146:15	65:18 67:9 74:10	
246:15 275:14	164:15 185:15	assisted 215:17	77:2 83:20 92:3	
appear 114:11,12	185:21 204:24	Associates 101:9	92:7 104:11	
155:5 174:7	217:22 218:10	association 7:17	107:13 115:4	
appearance 98:12	222:15,16 223:4	assume 87:11	117:2 121:22,23	
appearances 2:1	223:6,7 224:15	133:5	121:24 126:5	
107:22	area 208:24	assumed 132:18	129:23,24 130:5	
appears 98:11	areas 51:2 55:24	133:17 137:7,10	130:9 131:3,14	
107:19,23 143:9	81:17 201:9	138:15,18	136:4 147:14	
144:14 148:22	argumentative	assumes 40:18	150:8 152:10	
154:15 161:16	29:7 32:8,22	51:23	161:18,21 167:5	
169:4,5 208:17	40:6,12 49:8	assuming 142:11	173:24 174:18	
238:1 273:18	57:6,17 199:16	190:7	175:12 178:21	
275:18	arising 176:16	attached 174:21	187:12,21	
applicable 1:15	arrangement	175:3 284:16,24	188:20 192:3,3	
application 282:9	48:16 188:18,23	attaching 93:13	192:16 215:24	
283:5	239:11 257:14	attachment 5:16	216:14 251:10	
applications	arrangements	6:13,17,23	252:20 259:11	
279:23	70:9 134:20	171:14,24 197:8	265:6 272:10	
applied 121:19	arrived 179:13	229:7 234:10	bad 178:10	
apprised 12:24	articulation 152:8	247:11 262:19	bank 41:18 42:24	
appropriate 160:7	aside 39:8,9 84:6	attempt 90:10	43:10	
195:24 227:13	126:23	91:7 117:3,6	barstools 181:4	
230:10 247:5	asked 19:17 32:14	120:11,24	base 185:6	
approval 86:4	42:23 57:16	128:11	based 25:12 87:7	
195:2	64:21 66:13,14	attempted 101:13	95:9 96:3 121:12	
approve 28:21	85:23 101:3,7	114:17 121:1	122:1 193:7,8	
approved 22:20	127:21 130:2	167:17	basic 93:18 123:5	
22:22 133:24	138:24 158:9	attempts 120:11	185:10	
168:14 245:14	159:6 226:13,18	153:1	basically 25:16	
approves 20:24	227:2 235:6	attend 226:3		

ESQUIRE DEPOSITION SERVICES

1-866-619-3925

JT-A-1086

128:7 255:5	119:5,7,21,23	84:14 85:1	35:19,21 36:8	188:4 190:15,18
Basilio 3:21 4:3,8 4:11 5:13 77:21 80:12,22 87:2,8 89:1,8,16 91:15 93:12 96:17 110:2,14,21 111:19 115:15 121:15 126:13 127:1,19,20 149:9 156:19,20 186:12 189:10 273:18 274:4 280:18	120:3 121:11 122:1 125:1 127:8 131:9 138:14 139:6 140:19 142:7 143:15,15 145:7 151:13 152:12 152:12 157:4 158:23 166:21 169:19 171:9 175:17,22,23 176:1 179:1 189:5,14 190:22	132:13 133:5 136:22 168:2 210:14,18 216:19 218:19 224:20 225:18 225:19 248:8 250:16 Berenguer 79:13 162:11 Bernard 156:19 157:3 best 29:1 76:2 100:7 109:1 basis 15:15 123:3 129:18 147:6 164:23 181:10 241:16,20 batches 142:5,8,16 145:3,11,15 146:1 148:6 161:9,10,17,20 162:16 Bates 3:13 36:23 118:11 249:22 bathroom 107:7 becoming 215:13 began 59:7 61:3 62:20 65:10 83:22 beginning 124:20 234:22 252:6 284:16 begins 9:14 behalf 1:14 7:24 8:2 50:22 84:12 105:3,7,9 253:15 253:18 273:14 278:6,11 279:9 282:21 283:13 belief 106:21 124:14 believe 12:1,12,23 19:3 25:9 30:7 31:13 33:8,11 35:13,16 36:6 46:13 54:4 63:5 63:8 67:19 68:20 68:23 78:6 80:10 82:8 89:5 105:14 105:20 110:24 111:4 114:15,19	205:13 230:15 230:21 231:1 268:13 270:13 boat 180:3 Bob 12:19 203:14 248:4,11,12 259:15 268:19 boilerplate 134:11 boldfaced 201:19 Bolling 6:22 262:17 bonus 22:24 23:3 23:7 28:16 59:8 60:7,14,16 62:1 63:12,17 bonuses 23:12 61:7,20 62:23 63:11,20 69:11 borders 55:22 68:3 219:2 Boston 1:22 2:12 7:20 Bostwick 3:4 7:23 7:23 8:14 16:16 23:19 26:10,14 26:17 32:24 35:8 35:11 36:19 37:14,20,23 43:12 44:10 45:23 46:5 50:8 56:12 59:12,20 60:4 66:9,19 84:19 89:15 92:12 100:1 101:24 103:12 107:8 109:13 118:12 119:13 121:6 125:20,24 135:22 144:12 154:10,19 155:1 158:5,14 165:21 174:4 175:5 178:2,6,22 187:3	208:6 215:11 222:24 225:23 226:11,23 227:16 228:1 236:6 249:19,23 250:1,24 252:12 253:24 254:9 255:19 264:16 264:24 265:8,14 268:10,17 270:8 271:1,8,11,18 272:14 278:16 278:18 283:15 284:1 286:15 bottom 56:15 118:23,24 169:2 201:20 231:4 branch 237:17 branded 123:4 Bray 1:17 7:17 288:5,18 break 9:18 36:18 64:4 65:3 66:10 66:11 178:9 187:4 220:22 221:1 222:20,23 222:24 223:10 226:7 227:5,7,15 227:21 breakdown 60:23 70:8 191:21 breaking 9:19 breakout 193:20 breaks 9:21 bring 72:20 90:10 167:11 168:7 180:13 bringing 127:13 141:23 167:21 Bristol 225:7 broke 138:24 broker 220:5,6,7 220:17 brought 225:5 build 68:1 building 54:8 262:2 bullet 151:21 157:9 business 21:17 52:8 53:10 58:22

Page 292

72:7,12,20,24 75:3 76:8 81:24 104:7 105:24 106:2,8,11,17 149:19,24 150:10,16 161:24 162:23 163:22 178:21 185:2,4 274:19 283:1	C C 7:1 35:14,15 71:9 198:18 287:1,1 call 110:10 114:17 129:2,6 148:8 151:11 152:20 158:10,21 159:4 169:24 212:10 212:13 216:10 219:21 225:2 226:2,3 249:11 252:11 called 1:14 15:4 85:14 169:22 270:3 277:20 calling 272:22 calls 13:22,22 38:9 77:5 78:11 121:20 cancel 221:4,9,16 221:19 222:9 274:14 275:21 cancellation 226:19 capable 162:12 261:7 capacities 199:22 capacity 19:24 50:3 84:8 99:19 113:1 129:16 142:11,22 195:7 210:22 230:24 279:6,8,18 280:6 280:22 282:20 283:12 capital 43:3 card 72:7,12,22 cards 72:16,16,24 105:24,24 106:3 106:8,12,17	277:13 279:13 care 123:22 carefully 11:17 93:1 Carl 259:14 carry 55:21 231:12 Carta 5:10 174:13 case 1:7 7:11 9:13 11:5 83:10 109:20 112:12 125:16 151:9 208:15 224:3 245:6,10 254:19 cash 60:16 62:1 categories 114:22 115:1 caused 199:19 Celia 71:7 CEO 8:24 18:19 19:3 20:6 22:2 24:6 27:20 32:4 42:20 45:16 50:3 54:15 57:23 58:24 59:2,5 77:10 93:9 111:14 115:23 123:15 131:19 133:13,14,16 172:13 230:24 243:24 254:14 260:1 certain 47:6 161:20 203:23 215:12 217:17 281:3 283:9 certainly 9:24 25:13 53:21 57:3 60:20 80:1 83:18 107:8 149:8 191:22 214:4 certainty 235:11 235:17 CERTIFICATE 288:1 certify 287:2,5 288:8 Cesion 6:19 252:22 cetera 147:7 153:4 235:8 CFO 33:15 46:16	54:20 194:12 chain 237:19 chair 139:21 chairman 8:24 14:11 18:19 19:2 20:6 22:2 24:5 27:20 32:4 42:19 45:16 50:3 54:15 57:23 123:15 131:19 133:14 133:16 172:13 231:1 chance 253:5 change 92:13 201:3 238:5 245:8 changed 58:5,19 63:3 85:18 changes 53:24 151:17 152:7 character 113:3 characterization 39:17 45:21 49:7 93:22 138:13 231:24 237:24 charge 12:13 44:19 46:12 248:22 check 154:14 chemicals 124:1 chief 14:11 36:12 48:24 China 110:19,19 chitchat 178:21 choice 30:23 choose 32:5 chose 129:20 chosen 30:19 circumstance 129:20 circumstances 13:1 45:17 Civil 1:16 clarification 16:13 18:4 23:6 66:20 clarified 282:17 clarify 20:9 177:11 280:21 281:3,14 clarifying 67:4 Claude 77:15	135:18,20 156:23 280:24 clause 118:24 152:7 clear 15:22 25:7 32:3 189:17 242:5,11,21 clearly 46:9 126:12 173:4 242:6 Clemente 18:5 19:12,16 20:3 22:23 26:22 27:5 78:24 88:19 96:12,13 108:17 121:17 126:13 127:3,4,24 128:3 128:14 129:1 166:13 167:2 170:4 Clemente's 19:19 client 246:2 clinical 41:13 261:22 close 183:13,24 Cloud 159:4 coincidence 240:18,19 cold 252:2 collaborating 83:16 167:22 collaboration 90:12 168:1,6 collaborations 163:4 collaborative 81:16 collect 227:18 collecting 231:20 232:4 collectively 56:16 column 198:12,15 combining 83:10 95:20 come 20:1 35:2 78:2 93:16 146:9 252:5 262:10 280:16 282:23 comes 35:3 98:16 128:7 131:14 comfort 61:15 comfortable 38:16	235:18 coming 10:18 225:18 280:2 commencing 1:23 comment 38:11 commented 111:4 commenting 111:2 comments 111:6 114:21 132:20 commercial 42:24 43:10 191:16,23 241:5 242:9 commercializati... 257:24 commitment 112:24 207:5 271:5 272:24 commitments 162:13 committee 22:11 22:15 28:3 203:9 common 168:2 181:12 Commonwealth 1:19 288:3,7 communicating 127:7 275:21 communication 127:2 129:7 280:1 282:24 communications 127:22 companies 81:19 83:12 84:13 90:11,13 101:9 102:24 103:11 117:7 122:3,22 124:16 128:23 139:2 161:17 164:12 167:13 168:8 180:23 181:7,11,22 182:7 188:8 189:22 229:10 280:6,8 company 9:1 10:16 12:7 16:14 20:4 22:3,5 24:11 35:20 36:4 58:15 59:21 62:17 68:1,1,13
--	---	---	---	--	---

68:15 85:5 122:24 123:2,22 128:13 161:15 167:22 181:9 193:4 194:23 195:22,23 197:5 197:19,20 200:16 211:1 231:6 237:17 241:5 242:8,8 243:1 250:14 267:9 277:15 284:9 company's 190:8 231:10 232:23 compare 102:13 102:17,18 compel 43:17 compensation 22:10,14,16,18 28:3 47:20 59:19 60:2,13 63:20 203:9 competency 105:18 132:15 133:9 complete 36:4 39:5 49:20 185:17 261:4 completes 286:18 compliance 12:13 141:23 compliant 261:6 complying 12:14 Compra 5:10 174:13 Compromiso 5:10 174:13 computer 134:12 conceived 219:7 concept 111:23 112:1 concern 75:3 81:24 83:5 149:18 161:23 162:23 163:21 concerned 38:1 104:6 concerning 76:19 142:8 172:17 186:22 concerns 127:11	127:11,12 162:12 172:18 172:21 173:1,4 263:20 concert 133:24 243:7 Concha 260:20,22 conclude 100:8 concluded 286:20 conclusion 22:14 38:9 121:21 concrete 144:7 conditions 92:1,8 conducting 243:10 confer 176:2,3 conference 227:10 conferred 37:9 conferring 176:18 confidence 194:22 confident 73:2 confidential 59:18 76:18 224:2 282:7 confidentiality 3:20 6:15 75:7 75:13 76:6,15 165:18 245:16 245:20 246:10 264:9 271:20 272:11 confirm 211:7 223:16 230:20 233:22 262:22 confused 132:17 connection 93:23 93:23 240:15 consejero 35:3,10 35:13,23 36:3,9 36:14 38:6,17,23 40:3,9,16 68:7 195:8 consider 33:20 128:21 173:24 241:16 278:1,10 considered 174:2 262:16 277:2 considering 181:5 195:14 222:8 consist 33:5 consisted 60:13 185:1 consistency 14:23	consistent 12:9 110:16 122:17 145:14 248:23 consolidated 15:15 123:3 164:23 241:16 241:19 242:4 constant 149:10 consult 9:15 consultant 146:7,9 146:14 consultants 146:18 consulted 20:4 195:12 256:19 contact 78:15 81:23 83:4 149:10,15,23 150:7,9 162:22 216:7 279:5 contacted 131:24 263:19 264:4 contacts 75:1,2 77:2,5 104:5 149:17 161:22 contained 34:22 contemplating 216:13 contemplation 95:22 239:5 240:16 contents 133:23 134:2 245:14 context 94:1 96:5 109:20 162:7 175:16 203:1 211:21 280:14 contexts 74:24 279:3 continuation 184:14 continue 46:7 121:2,9 124:16 145:24 147:9 148:20 194:19 200:4 223:2 continued 4:1 5:1 6:1 143:13 188:17 216:20 continues 60:1 continuing 63:19 199:23	contract 82:7 95:9 96:3 100:20 110:4 113:11,15 115:3 116:7,10 116:11 117:13 150:15 152:15 152:22 153:1,3 167:20 221:9 222:20 226:19 229:8,19 246:7 264:13 273:10 273:11,22 275:22 contracts 151:15 151:16 152:10 152:17 175:14 176:10 221:4 contractual 101:8 Contrato 5:9 6:19 174:10 252:21 control 20:4 31:15 132:18,23 133:6 133:17,20 134:5 137:7,10 138:15 138:18 141:15 153:3 243:13 conversation 114:12 191:6,9 212:6 conversations 13:24 79:5,8 180:19 converse 78:23 conversion 266:18 convince 13:18 coordinate 249:11 269:9 coordinated 244:10 coordinating 200:11 copier 54:6 copy 5:15,19 6:12 6:16,21,22 125:23 129:1 175:3,4 197:6 205:12 234:9 247:9 260:10 262:17 copying 37:17 core 185:4 corporate 122:13	122:18 123:18 corporation 3:23 15:5 16:14,15,17 18:2,24 19:5,6 80:24 81:3,9 83:9 84:3,10 85:8,15,18 93:4 97:16,18 98:3 100:6,7,14 102:2 105:11 111:14 115:22 124:4 239:3 Corporation's 99:19 Corral 2:20 8:4 Correction 287:8 corrections 287:7 correctly 63:10 94:21 153:9,10 166:24 181:20 221:6,17 271:6 282:11 correspond 112:24 cost 145:20 costs 127:11 couches 181:2,3 182:5 counsel 7:21 8:5 9:15 13:24 37:7 109:19 198:22 200:16,18 240:4 269:2 counselor 38:5 89:13 92:10 counsels 243:23 counter 52:23 counterpart 129:19 counterproposals 143:18 countries 56:1,2,3 56:4 233:4 couple 37:12 64:4 65:1 156:3 171:10 179:24 226:7 227:13 270:17 278:16 283:21 course 21:17 58:23 68:4 128:20 142:1
--	--	--	--	--

Page 294

192:11 210:23	67:4 75:17 83:20	129:17 137:16	103:16 104:5,17	35:14,24 36:3,10
215:24	87:22 95:12	de 2:18 3:21 4:3,8	251:1,3,15,24	36:14 38:6,18,23
court 1:1 7:10,16	106:12,18,24	4:11 5:9,10,10	decide 196:15	40:3,10,16 68:7
8:8 9:10 10:3	156:14 158:3,4	5:13 6:19,19,19	decided 191:7	195:8
13:18 27:19 28:2	182:18 189:16	17:17 77:21	207:7 219:9	delegate 36:5
28:8 32:3,18	190:1,23 198:3	80:12,22 87:2,8	decision 17:16	delegated 38:5
35:11 40:2,10	199:8 200:14	87:17 89:7,16	18:5,13 19:11,19	delegating 38:6,22
51:21 56:12	208:17 221:12	93:12 96:17	19:22 124:22	38:23
137:13 138:17	221:21 225:2,5	110:2,21 111:19	188:22 189:2,4,5	delegation 34:22
courts 176:17	225:18,21 226:5	115:15 121:14	189:14 190:5,16	35:1 86:16
cover 117:13	226:10,14	126:13 127:19	190:17 193:1,7	delivered 104:2
247:16 263:2,2	227:19 239:4,16	156:20 174:10	193:23 194:3,18	243:15 263:9
cracks 269:12	246:16 250:22	174:13,13	194:24 196:19	delivery 58:16
Craig 2:13 8:2	267:23 270:20	186:12 189:10	196:23 197:1,4	72:21 76:23 94:4
37:14 178:16	272:11,15	239:1 252:21,21	216:11 222:20	163:3,7 168:1,3
265:10	285:17	252:22 280:17	262:4 271:12	180:21 207:12
created 239:2	dated 3:22 4:3,8	deadline 213:15	275:21 276:6	218:18 241:5
245:4 251:2	4:12,13,17,19,21	213:16	decisions 17:6	242:8 243:18
creating 41:19	4:24 5:4,6,7,12	deal 58:17,18	20:18 27:11,17	271:23 279:21
43:2	5:14,16,20,23	129:14,19,20	29:3 194:23	282:9
credit 41:20 42:5	6:4,7,11,13,14	191:12	195:21 222:12	delivery-based
43:2 47:20	6:17,21,23 80:13	dealt 207:15	declaration 3:8	258:12
credits 47:21 48:4	89:17 107:20	dear 70:21 217:15	10:23 11:4 12:9	demand 95:8 96:2
48:8	110:22 111:17	284:15	13:7,10,18 14:5	96:8
Cremides 101:9	114:8 115:16	DeBregesas 4:13	14:6,17 16:3	Denube 156:19
criminal 10:7	116:18 123:12	4:18 5:5,7 77:10	17:2 27:9 29:12	157:3
crossed 199:18	125:5 126:12	89:3,8 96:17	31:20 34:13,16	department 88:9
CSR 1:18	130:21 144:9	101:12 108:8	39:10,12,19 41:2	256:9 260:8
Cubas 2:18	154:6 168:22	114:13 115:2	41:8 51:10 56:19	departure 87:19
cumulative 62:9	170:22 171:3	116:6,17 117:9	57:21 66:22	135:6
current 8:23 18:9	182:10 189:11	121:14 130:20	73:24 120:15	depend 50:14
33:4 153:8 224:8	197:7 205:13	131:3,4 166:13	136:9,15,21	dependent 41:4
236:9,17 238:20	212:21 214:10	167:6 169:12,15	137:12 138:3,9	51:10,15
251:11 256:18	215:5 217:1	170:10,21 171:2	138:22 147:15	depends 72:17
currently 20:13	228:17 233:14	172:9 173:1	149:12 161:21	deponent 7:3
40:22 63:2 95:1	236:7 239:14,17	276:20,22 277:1	declared 47:21	deposition 1:13
235:4 236:23	245:19 247:10	277:7,23 278:4,9	Defendant 1:10	7:6,12,16,18 9:3
262:1,15	247:15 248:2	280:17 285:15	2:9 13:11	9:14 11:21 43:18
customer 185:6	260:11,14	285:17	Defendants 7:10	59:14 61:1 78:19
246:21	262:18 274:22	debriefed 109:9	define 90:7 101:19	92:17,22 166:1,7
customers 176:15	284:3 287:17	110:9 152:13	122:24	226:4 228:9,15
185:11 263:13	dates 63:24 65:20	187:2	defined 101:15	286:19,20
263:19,23	87:10,11 106:1	debriefing 110:11	198:5	288:10,11
cut 124:2	186:1 227:12	110:16 111:8	defining 58:20	DeRoche 70:20
D	date's 260:16	113:18	definitely 152:19	71:2,3
D 2:7 3:1 7:1 34:2	day 75:18 172:8	deceased 79:15	definition 91:24	describe 40:9 46:6
34:3 35:15,15	174:8 240:13	December 80:13	degree 61:15	58:2 67:22 68:10
218:12	245:19 246:5,7	80:21 81:14	176:23	74:23 122:23
damages 13:15	287:18 288:16	84:22 85:9,14	Delaware 1:2 7:11	123:3 126:23
data 225:15	days 87:1,4 110:19	86:22 87:13,20	231:7 232:21	183:7
date 17:20 19:4	177:1 260:18	88:18,24 96:10	239:3	describing 60:11
	day-to-day 68:4	96:18,22 99:1,20	delegado 35:3,10	94:3

description 3:7 4:2 5:2 6:2 39:13 123:18 124:3	different 60:12 68:23 74:2 121:7 138:7 160:18	disapprove 28:22 disclosable 205:4 disclose 27:19 28:2 40:2 51:21 59:22	164:22 176:11 177:4,14,17 182:1 184:1 186:22 234:22 268:2 272:18	262:9 doubt 86:10 dozen 228:20 Dr 27:5 116:1,2 129:13,15
designate 93:8	173:20 179:6	disclosure 3:20 93:13	268:2 272:18 276:21 279:20 283:2	draft 4:5 5:24 90:2 92:3 101:10 107:3,19,23 110:2,14 120:24 151:15 152:22 164:17 165:6,18 168:12 214:11 214:23 215:18
designated 30:20	185:23 194:20	disclosures 12:2	176:16	229:7 269:23 274:8 277:17 284:17,24
designation 204:1	194:21 197:24	dispute 130:12	distinct 13:20	drafted 73:17 244:14 266:21 274:1
designed 244:10 244:12	232:2 233:4,5 238:14 268:1,1,2	discretion 270:19	74:24 179:10 181:12 242:22	drafting 273:21 drafts 109:4 117:2 152:9 244:17
detail 50:20 142:9 183:3	269:21 270:11 279:3 280:6	discuss 43:19 49:12 88:9	123:23 184:19 255:3	dramatically 63:4 draw 139:23 165:13 194:9
details 13:3,4 108:16 162:13 163:7 180:20 239:11	283:5,6	direct 22:7 147:12 150:9 244:2 273:20 274:8	District 1:1,2 7:10 7:11	drink 9:22 driver's 7:2 drug 58:16 72:21 94:3 163:3,6 168:1,3 180:21 207:12 210:10 210:12 218:18
determine 32:12	Diplomate 1:18 288:5,19	directed 25:6	division 57:9	241:4 242:8 243:18 244:1 258:11 271:23 279:21 282:9
develop 90:3,4 103:3,21 164:11 218:6	directing 210:22 274:11	directing 210:22 274:11	divisions 53:6 55:1 55:4 57:11	drugs 76:20,23 123:24 272:1,7 282:8
developed 41:9,14 219:9	direction 243:13 257:17	directly 37:8 88:7 88:13 120:7	discusses 25:10 149:12	Dodge 1:21 2:10 7:19
developing 15:22	directors 3:10,12 3:16,23 4:15 6:9	discussing 93:18 93:22 100:19	discussion 83:18 86:8 101:6 126:3	Dubois 4:16,21 77:15 125:4
development	35:6 57:21 91:16 277:18,21 285:24 286:1,3	147:1 150:14 161:2 176:22	134:14,19 135:12 141:12	135:18,20 139:8
53:10 90:11 103:5 185:2 217:16,20 218:1 218:3,6,8,20 219:1,5,6 235:4 235:14 236:24 237:8 266:14	directors 3:10,12 3:16,23 4:15 6:9 20:24 21:7,14	181:4 182:13 186:6,24 187:1	142:4 175:10 184:14 228:12	140:3 143:19
developmental	director 14:12 22:23 23:15,22	193:23 194:2 222:7 234:6,8	193:23 194:2 222:7 234:6,8	144:8 147:2
218:13,15,16	35:6 57:21 91:16 277:18,21 285:24 286:1,3	256:24	174:6 177:15,21 228:20 236:1	148:18 149:5
diaries 109:18 112:11 114:8 151:8 202:24 223:17 226:3 227:9	discussion 83:18 86:8 101:6 126:3	discussions 13:24 73:5 80:9 91:16	240:4	156:19,23
diary 4:7,9,10,20 4:22 5:3,17,21 5:22 6:5,6,18 109:10 112:6 114:3 140:10,13 151:5 155:24 156:4,10,11 202:13,18 208:8 208:10,13,14 211:3,8 219:15 219:19 223:13 226:5 250:20	24:2,17 28:3,9 28:18 29:15	96:16 103:18 108:13 121:13	dollars 41:19 43:1 dosage 94:24 95:14	280:24 281:2,14
differ 270:16	30:14,19,24 31:2 31:11,21 32:2,6	122:7 205:22,24	dossiers 261:4,10 261:14,20 262:1	due 46:1 207:4 271:5 272:24
difference 59:1 178:12 193:12	32:20 34:23 35:2 36:9 38:21 42:12	206:1,12,13	128:4 178:10 195:14 220:9,14	duly 8:9 288:10
differences 127:2	73:8,13,19 85:8 122:7 205:22,24	230:16 231:8	220:17 230:7,11 248:22 261:13	duties 10:16 40:9 55:17 58:2,20
	268:13 270:13	268:13 270:13	269:22	
	dirty 180:8	disagree 195:17	dosage 94:24 95:14	
	disagreements	130:12	dossiers 261:4,10 261:14,20 262:1	

Page 296

59:2 67:20 68:10	274:13 276:8	enhancement 76:19 271:24	essence 88:15 essentially 68:11	everybody 251:21 251:24
Dwight 7:23	277:6	272:6 283:4	113:17 127:9,21	evidence 40:19
D.C 2:6	elect 31:1	ensure 98:3	134:5 148:13	51:24 232:1
	elected 30:5 32:18	100:15	167:8 184:15	evolved 58:6,19
E	elections 29:24	enter 88:22 100:8	229:3 250:6	exact 19:4 65:12
e 2:13 3:1,6 4:1	elects 29:14 30:14	100:14 161:10	87:22 106:18	87:22 106:18
5:1 6:1 7:1,1	31:21 32:1	161:10	189:16 199:8	189:16 199:8
12:21,21 34:1	elevated 19:2	entered 246:15	256:3,8 258:10	256:3,8 258:10
35:14,14,15,15	eliminate 185:9,10	264:8	exactly 26:5 39:1	
71:9 207:3 250:8	eliminating	enterprise 58:21	45:4 46:5,16	
263:13 270:24	184:17 209:16	enters 246:9	110:8 136:12	
271:4 287:1,1	elimination	entire 38:14 39:6	145:1 154:19	
earlier 27:10	184:20	66:7 162:7	215:11 233:2	
96:15 136:20	employ 100:7	entirety 25:4	EXAMINATION	
164:21 212:21	employed 8:20	44:24	8:14 265:9	
233:23 234:16	59:9	entities 48:3 84:13	example 61:18	
249:14	employee 17:10,14	85:6 235:12	71:22 147:22	
earliest 190:11	18:10,10 23:9	entity 64:13	149:22 191:4	
191:3	employees 17:5,6	115:23	235:10 259:19	
early 65:15 81:4	20:18,19 23:16	entity's 47:7,10	280:16,20 281:1	
97:12 102:10	24:19 25:19 26:3	50:9	281:22 282:10	
132:24 155:7	27:11,12,16,18	entries 5:22 211:3	282:12	
168:15 187:21	28:10,11,20 29:2	226:6,10	examples 74:9	
188:4 190:11	29:3 31:17,18	entry 4:7,9,10,20	exception 287:7	
207:9 213:9,13	65:2,6,9,21 66:1	4:22 5:3,17,21	exceptions 9:19	
easier 150:6	66:5,17,24	6:5,6,18 109:10	exchange 59:21	
171:11,19 172:2	235:21 266:1,1,3	112:6 114:3	165:2 235:2	
178:13	employment 17:5	140:10 151:5	256:18	
easiest 67:22	20:18 27:11,17	155:24 202:13	exchanged 151:15	
easily 243:24	29:2	208:10 211:12	Exclusivity 152:1	
easy 144:24 280:4	enact 146:17	219:15 223:13	Excuse 160:23	
economical 145:3	enacted 146:15	250:20 274:22	222:22	
economically	enclose 117:13	entryway 53:2	executed 11:14	
145:20	encloses 214:23	EP 3:14 36:24	175:17,18	
edit 245:8	enclosure 5:8	118:11	executive 14:12	
edits 53:24	117:12 171:4	EP002866 3:14	34:5 36:13 48:24	
education 143:10	encompasses 44:9	36:24	55:19 68:12	
Edwards 1:20	encountered 140:6	equal 259:20	277:18,21	
2:10 7:19	encountering	126:21	285:23 286:1,3	
effect 193:18	126:21	equals 142:16	executives 50:14	
effectively 33:17	encouraging	186:23	exhibits 105:14	
64:8	184:4,6	equipment 186:19	136:7 177:13	
effort 235:1 262:2	endorsed 177:2	186:23	234:17	
efforts 100:7	engaged 101:9	equivalent 23:3,4	exist 135:4	
eight 66:3	122:24 123:22	error 15:16	existing 95:7 96:4	
either 27:4 70:22	English 78:21 79:9	erythromycin	124:22 148:2	
74:4 77:8 85:6	79:22 80:2,5,7	81:18 83:14 90:5	161:14	
87:22 89:7	108:3,19,20	90:15 95:15	exists 238:20	
100:17 142:17	117:19 125:22	102:5 104:2	expand 55:22 68:2	
170:14 185:16	137:18 157:19	Espana 239:2	81:16 94:9,16,22	
186:21 212:4	253:4 254:5	especially 266:15	167:18 183:20	
226:6 267:3	273:9	Esquire 2:7,13,20		
		2:21 7:15,17		

185:6,9,10	F	244:2 261:10,16 262:2,6 269:23 filed 179:2 205:3 125:4 126:12 130:20 131:24 132:5 154:5 166:21 168:21 169:6,11 182:9 182:15,21 186:7 214:10 216:24 218:21 228:16 229:2 233:13,19 233:20 faxed 172:9 faxes 233:24 February 36:1 75:19 140:10 143:7 144:9 150:22 203:5 205:11 207:9 213:22 272:13 Federal 1:16 fee 255:7 267:11 feel 38:16 39:18 40:1,8 73:2 195:1,23,24 235:18 243:5 245:7 261:24 feels 25:5 fees 44:18 46:2,12 255:3,9,15,17,20 255:21 267:8,9 267:12,13 fell 269:11 felt 19:16 101:7 128:3 138:20,23 190:8 195:11 197:4 270:14 Fernando 79:13 fifteen 24:19 25:19 26:6,7 28:10 fifth 102:23 269:17 figurative 67:23 figure 160:2 figures 193:19 file 29:22,24 188:23 203:11 203:22 210:10 210:12 224:16 225:24 243:14	206:9 211:6 241:11 242:6 267:21 269:17 273:20 279:5 284:14 285:13 fit 199:15 Fitzgibbons 5:16 5:19 6:16,23 197:7,15 205:13 247:10 262:18 270:11 five 89:13 155:6 185:7 224:17 225:8 249:15 264:19,20 fix 189:8 fixed 112:21 flights 70:8 Florida 251:15 252:3 focus 58:6,23 67:24 180:20 follow 225:4,12 269:20 followed 29:20 148:13 following 48:2 210:14,18,20,21 217:21 follows 8:12 font 98:17 food 70:7 237:19 foregoing 287:3 288:13 forever 286:15 forgave 44:24 form 90:4 154:5 formal 71:13 175:24 193:20 196:14 264:11 formality 73:14 formed 238:24 239:4,5 forms 94:24 95:14 formulas 223:4 formulation 159:14 160:13 161:6,7 164:4,6 164:7,8,10,11 185:15,15,16,17 185:20,22 194:21 207:16
------------	----------	---	---

Page 298

217:23 224:15 formulations 88:13 95:17 204:24 forth 10:17 92:4,7 115:4 117:3 150:9 152:10 227:12 238:21 288:10 forward 193:4 207:21 224:22 for-discussion 236:14 foundation 49:17 158:15,16 four 33:5 87:4 181:22 182:7 221:5,7,8,9,11 243:8,14 244:8 244:22 258:8,13 258:21 259:1,12 274:15 fourth 101:23,24 269:17 frame 17:23 96:9 96:15 100:9 110:7 154:4 176:20 187:17 189:9 framework 93:18 147:7 161:13 France 1:4 7:8,24 58:14 77:10,13 77:16,19 81:13 90:20 91:4,10,12 91:13 96:22 124:1 131:16 135:17 156:23 177:15,17 181:23 272:4 276:18 frankly 49:19 free 25:11,13 French 118:6 frequent 270:14 frequently 138:1 164:22 Friday 5:18 202:14 203:5 front 36:16 105:2 141:2 263:3 frustration 128:11	G 7:1 35:15 207:14 248:4,11 248:12 268:19 274:12 GAAP 266:19 Galenic 88:9 Garcia-Palencia 2:21 8:4 Geez 179:24 gel 257:20 general 17:9,12,17 18:6,14 19:17 20:10,24 27:4,6 27:21 28:4,5,6 28:12,13,15,17 28:18 39:21 50:22 55:9 62:11 74:20 77:15,18 77:21 78:11,16 78:24 87:17 91:17 96:14 106:21 108:14 108:14 120:19 127:4,6 131:11 131:11 147:19 148:11 149:6 170:5 216:2 267:6 generalized 121:20	generally 16:19,22 70:8 74:3 77:3 121:13 generate 197:21 218:2 generated 193:11 219:6 generic 52:20 123:4 224:14 261:16 262:12 generically 262:3 generics 261:10 gentlemen 158:18 178:21 Gerard 77:12 185:24 284:3 Germain 5:12 77:18 179:4 182:9,16 186:7 186:10 Germain's 179:14 179:15 getting 70:24 108:15 143:10 248:14 261:8 283:23 give 8:15 12:5 20:2 39:20 46:21 50:19 53:11 60:7 60:17 61:15 70:17 72:7,14,15 72:16 85:5 109:13 143:11 144:6 148:8 149:1 154:3 178:23 182:12 211:20 234:24 242:2 246:5 276:9 278:21 280:15,19 281:12 goals 55:21 goes 59:17 going 10:21,22 14:22 15:18 21:10 31:19 36:21 37:5 43:17 46:21 63:18 64:4 67:6 70:18 75:10 81:13 84:18,21 85:22 94:16 98:22,24 99:23 100:1 101:19 105:19 106:14 107:10 115:4 123:18 124:14 125:12,18 126:2 127:22 128:8,17	136:1 139:1 148:17,24 150:21 154:11 154:21 161:21 168:16 171:1 174:4,5,16,17 175:8 178:18,20 180:7,12 181:5 183:23 187:9 190:22 191:11 192:3,3,16 196:10 202:16 202:16 210:1 213:21 226:1,2,2 226:8 227:4,6,14 228:5 230:2 232:11 237:7 245:18 248:19 249:6,8,11 251:7 252:10,17 253:1 255:6 257:17 261:10 263:20 265:3 275:4 Gonzalez 18:6,14 19:12,16 22:24 26:22 27:5 78:19 78:24 80:1,2 88:20,21 96:12 96:13,16 108:17 121:17 126:13 127:4,24 128:12 129:1,13,15,18 129:23,24 130:5 130:9 162:11 170:4 Gonzalez's 22:17 166:14 good 64:5 78:21 80:6 98:3 118:3 127:12 136:5,6 141:24 157:19 159:11,13,14 160:12 161:4 174:23 187:4 195:22 228:3 260:16 gotten 114:20 granted 24:11 38:12,13 39:4 42:4 granulation 209:11
--	---	---	---

graph 238:1,4	handy 281:8	185:6 186:13	hiring 88:6 95:3	211:5 214:13
great 58:17,18	happen 25:24 42:7	197:24 260:2	historic 180:15	217:2 219:16
GREGORIO 2:20	95:22 196:10	267:24 268:4	history 167:23	223:14 228:18
grew 58:18	237:7	helped 101:1,2	hold 19:21 40:15	230:18 233:15
grounds 63:20	happened 86:6,11	helping 143:22	40:21 64:18	234:12 239:19
133:9	139:18 149:4	158:1 201:3	67:13 68:6,18	245:17 247:12
group 122:2	251:22	259:3	73:11 199:1	250:21 252:24
241:21 245:7	happening 111:9	helps 141:9	holding 126:7	260:13 262:20
257:6,7	244:5 263:17	hereinbefore	178:7 237:17	identify 165:3
grow 81:20	264:11	288:10	honored 168:17	imagine 145:15
growing 194:23	happy 107:15	hereunto 288:15	Horvath 5:15	immediately 10:1
guess 69:14 123:7	175:3 228:19	Herrera 5:14 6:4	197:6 198:20,21	15:23
143:21 184:5	hard 137:16	19:12 20:10,14	201:12 231:9	implemented
guidance 51:4	179:16	27:1,4 28:16	232:20 233:9	238:14,17
guide 50:15,16	hat 180:23 225:10	33:6,10 34:8,17	257:10 268:24	implications 233:5
51:2 243:20	225:10 280:10	36:7 37:9 38:7	269:1,5,15	implicitly 276:9
guiding 39:2	281:5,16 282:2,4	40:17 54:24 55:3	hot 198:1	importance
195:22	282:13;19	55:11 57:10	154:15 155:5	254:21
gut 143:8	283:10	79:21,22 137:23	hotels 70:7	important 10:11
guy 179:23	hate 92:5	137:24 162:11	17:13 27:19 28:1	17:13-27:19 28:1
guys 178:14	head 9:11 60:17	175:18 176:3,10	28:7 32:2,17	
Gyurik 259:15	60:21 97:22	186:12 187:1,2	39:18 40:1,9	
<hr/>		189:3,11 190:4	51:20 122:22	
H		190:14,15 193:1	128:22 137:11	
H 3:6 4:1 5:1 6:1	headed 5:17	194:5 195:2	138:17,21,23	
8:18 12:21	202:13	203:17 208:21	impossible 60:18	
half 203:19 259:17	headquarters	210:14 216:24	impression 242:2	
259:20 264:21	14:18 16:20 19:9	217:7,10,12	improved 145:17	
265:1	53:1,6 54:8 81:6	218:1,19 219:10	145:18 209:10	
halfway 211:12	93:5 98:4 105:3	219:22 230:6,6	243:14 263:9	
Hampshire 7:2	105:15 131:15	234:7 246:15	improvement	
58:15	131:15 133:15	252:5 256:19,24	185:20	
hand 53:9,11 55:6	133:19 219:7	260:23 273:16	improvements	
107:14 126:7	244:11,12	274:8 276:1,6,9	193:6	
208:12 240:2	health 123:21	276:13	inches 283:22	
277:13 288:16	hear 46:10 107:15	Herrera's 34:21	incident 139:1	
handed 189:17	heard 13:4 176:17	39:13 80:5	166:10,20	
240:4	heart 9:22	hesitate 38:11	include 58:20	
handle 200:12	Hebert 12:19	Hey 216:10 251:21	91:19 108:6	
201:15,21	held 7:12,18 12:22	hide 226:14	113:14	
handling 141:14	21:20 35:23	high 160:2,5	included 217:21	
handwriting	38:17 39:20 40:2	198:18	includes 153:3	
108:1,3,4,22,24	67:18 68:22 78:7	higher 65:16,16	217:21	
109:1,16 112:9	139:12 199:2	65:16,18	including 17:6	
114:6 117:19	230:21 237:13	highest 35:19,20	20:19 27:12,18	
118:1,6,7,9,19	Helm 220:1,4,5,14	highlights 206:16	29:3 56:17 102:4	
118:22 119:2,3,9	220:15,16	270:20,21	108:10 243:15	
119:15 156:12	help 80:11 108:21	highly 184:16	263:9	
203:3	127:14 130:2,7	hire 18:5	inconsistent 57:3	
handwritten	148:15 154:3	hired 18:11 27:21	122:17	
118:15 219:18	155:8,14,23	hires 17:5 20:17	Incorporated	
249:15	165:13 168:7	27:10,16 29:2	277:4 278:7,13	

Page 300

286:8	input 111:22	66:13	169:16 173:7,15	129:2 130:21
incorrect 102:12	112:1,4 243:12	interview 166:22	186:18 187:19	131:7 136:16
102:15	insert 245:9	167:2	194:14 195:18	137:6 249:9
increase 23:1,2,6	inserted 113:19	intimate 129:15	196:16 199:18	253:11 260:11
25:10 63:1,6	inside 197:17	intranasal 232:17	233:7 234:18	260:15 262:18
87:24 88:4 96:8	instance 130:4,15	258:11	240:10,10 257:4	262:23 263:18
167:19	230:11	introduce 7:21	258:15	263:22
increased 88:4	instructing 60:4	280:18	issued 60:12	Japanese 133:17
96:2,11	insulin 258:11	introduced 140:7	189:15 205:4	Javier 101:10
increases 23:12	intellectual 170:11	introductions	240:8 263:11	Jean 70:20 71:2,3
increasing 95:8	231:10 232:11	53:13	issues 9:24 48:19	71:3,6
167:12	232:23,24 233:3	introductory	63:21 115:12	Jim 53:9,11 55:6
indefinite 124:13	235:3,7,13	52:18 83:21,23	140:22 141:16	74:12 201:12,20
independently	236:23 237:7	106:5	142:21 143:17	203:15 217:15
52:4 56:20 57:1	238:11 250:15	inventors 235:21	146:11 151:17	Joannesse 5:4 6:7
57:13 140:23	250:16	investor 244:19	152:9,14,21	6:11 78:4 168:22
164:11 193:4	intent 4:4 14:1	invoiced 112:22	170:6 198:1	228:16 229:2
219:9	97:1,11,15,22	involve 134:19	201:16 206:20	233:13
indicate 105:1	102:24 103:10	involved 48:20	207:14 225:16	job 60:10 195:22
111:21 158:19	231:12	74:13 86:14 88:7	227:17 248:5,19	John 33:24
279:1,16	intention 100:13	88:14 110:5	258:5 259:3	Johnson 133:15
indicated 261:3	276:2	120:8 129:11	268:19 279:8	133:15,16,16
indicates 11:8	interact 200:18	136:22 137:3,15	item 116:16	joined 197:19,19
47:5 66:23	243:20	137:16 138:6,11	145:16 163:24	joint 90:20 91:3
156:17 160:9	interacted 279:2	150:13 151:1	164:16 206:24	100:8 102:3
176:1	interaction 149:13	154:1 162:22	212:16 227:19	joking 179:18
indicating 94:7	interactions 74:24	163:16 192:2,15	249:5 251:3	Jonathan 2:7 8:1
143:21 277:14	intercede 127:21	199:21 200:3,8	256:4 268:18	Jordan 198:20
indication 24:9	280:1	200:11 201:2	271:2,4 275:4	233:9 248:4,5,8
109:22 158:18	interest 64:19	206:6 244:18	items 5:18 114:18	248:22 249:2,8
158:19 161:13	105:11 279:22	248:14 257:10	114:24 115:1	249:11 257:10
212:20 216:19	interested 83:16	273:21	201:12 202:5,13	268:19,20,23,24
220:13 222:19	interesting 184:21	involvement 41:10	203:5 204:9	269:1
226:21	interests 83:12	74:4 128:2	225:8 249:15	journal 274:19
indications 118:15	134:1 168:2	involving 85:24	250:12,13	judgment 276:13
159:17	180:22 181:12	286:11	it'll 198:11	July 1:22 7:12
individual 12:18	190:9 193:3	in-house 198:22		23:22 24:3 92:16
59:19 157:1	195:23 211:1	269:2	J	92:21 116:18
individuals 203:10	intermediary	IP 200:12,12	J 35:14 201:12	117:10 120:9
259:16 279:13	200:15	235:21 236:22	James 1:13 3:3,8	165:24 166:6
individual's 59:19	intermediate	237:12,16	7:6 8:9,17 10:23	219:15,22 222:8
inform 28:8 32:17	61:11 200:15	248:22	13:11 92:18,23	228:8,14 286:17
informal 181:10	internal 274:24	IR 245:6	93:9 131:18	287:4
information 10:12	internally 146:13	Ireland 55:23	134:8 166:2,8	juncture 128:22
12:6 13:23 59:18	262:5	Irish 238:23	228:10,15	151:2
76:18 142:7	international	irrelevant 158:13	285:23 286:19	June 115:16
informed 24:10	123:21	issue 43:14 49:11	287:2,19 288:9	214:11 215:5
ingredient 160:22	interpreter 38:13	49:12 50:15 60:3	January 93:14,15	216:21 217:1,7
initial 131:10	38:14 39:2	70:4 127:10	96:10,18,22 99:1	229:4,20 233:20
231:7	interrogatories	129:5,10 130:6	99:20 103:17	233:23 284:3
initially 126:11	175:24 179:2	130:11 141:22	104:6,16 125:5	justify 255:2
181:15	interrupt 64:3	166:12 169:12	126:12 128:7	

ESQUIRE DEPOSITION SERVICES

1-866-619-3925

JT-A-1096

K	240:12 243:2,9 243:16 244:9 262:9,10,12 263:10 large 124:15 195:19 larger 171:12 largest 27:6 62:1 157:11,17 late 19:3 95:12 102:10 132:24 155:7 262:6 Laura 4:24 79:4 154:5 law 7:18 8:5 73:18 226:13 laws 38:10 lawsuit 10:18 13:1 13:2,8,14 202:19 203:1 211:10 lawyer 200:20,22 lawyers 110:3,4 110:15 215:17 248:14 leading 268:10 leads 114:19 leap 91:22 leave 10:11 162:18 163:8 199:5,7 leaving 137:12 Leduc 5:23 77:12 110:18 167:6 185:24 186:3,10 214:10,20 215:5 215:12,24 216:7 216:18 233:24 276:19,22,24 277:7,22 278:4,9 284:3,24 Leduc's 229:4 left 68:5 199:14 leg 180:5 legal 7:15 20:13 37:8 38:9 length 245:1 lengthy 39:12,17 letter 3:21 4:4,21 5:5,13 71:21 72:1 80:12,21 83:9 84:11,12 87:1,8 92:24 94:1 97:1,11,11	97:15,21 104:17 104:17 128:6,7 129:2 131:2,7,10 132:12 133:14 133:24 134:2 136:16 137:6 144:8,16 150:20 164:17 165:6 170:3,18,21 171:2,9,11,20 172:1,8,17 173:2 173:16 189:6,8 189:10,15,21 190:1,6 194:16 196:11 215:4 216:8 218:20 229:4,13,14,16 229:17,20 239:13,14 263:2 275:23 284:3,6 284:24 letterhead 71:22 72:2 80:24 105:2 115:22 172:11 letters 71:16,19 150:8 165:1,2 162:19 224:17 250:5,6,12,13 let's 14:4,10 15:22 17:2 21:3 29:11 52:2,24 54:3 57:20 61:11 66:21 73:8 80:9 92:24 94:5,6,7 96:24 97:14 99:6 99:17 100:1 101:21 102:23 104:13,18 112:5 114:2 116:16 118:3 141:9 148:20 149:11 153:14,15 158:2 159:7 165:21 168:3,4 170:2,19 174:3 178:21 180:2,6 181:14 197:18 201:8 202:12 205:10 206:9 213:19 215:3 216:23 219:14 227:23 241:10 280:15 level 101:5 108:11	local 131:10,11 location 140:21 locations 179:10 181:13 logical 235:23 long 12:22 67:18 71:3,10 89:11 134:20 180:19 197:16 199:1 longer 26:23 198:23 199:3 look 11:7 13:5 14:4,10 17:2 21:3 25:8,13 27:8 29:11,13 37:15,19,22 46:24 47:25 1:8 52:2,13,24 57:20 75:10 80:17 85:21 92:24 94:6 94:8 95:13 98:17 100:2 101:21 102:23 103:22 104:18 112:5 116:16 118:3 122:10 136:8 144:3 149:11 153:14 156:2 158:22 170:19 171:18 174:3,9 175:4 181:8,9 198:1 201:8 202:12 203:24 206:8,9,24 207:3 207:14 208:23 212:16 213:19 215:3 216:23 217:3 219:14 226:9 231:3 236:2 239:20 241:10 247:24 249:7,21 250:4 250:15 253:5 261:12 looked 19:18 64:12 99:7 120:21 131:7 140:7 174:20,23 212:21 221:22 233:7 239:13 looking 21:11 55:22,23,23
----------	---	---	--

Page 302

56:19 67:24 68:1 72:20 83:11,20 95:12 103:24 104:13 136:15 136:19 140:23 141:8 142:3 157:22 165:12 183:18,19 208:3 227:18 230:19 238:9 239:23 248:21 259:11 262:6 looks 75:18 118:5 lose 70:16 lost 178:19 lot 9:22 25:8,8 194:22 262:7 low 198:18 lower 65:14 lowest 65:24 ludicrous 153:2 Luncheon 136:2 lunchtime 179:24	199:16 202:8,9 230:9 255:2,7,9 255:20 267:8,12 manager 17:9,12 17:17 18:6,14 19:18 20:10 21:1 27:7,21 28:5,12 28:13,15,17,18 55:9 77:15,18,21 78:16 79:1 87:17 96:14 108:14,14 127:5 131:11,12 148:11 170:5 216:3 managers 27:4 74:20 78:12 120:19 127:6 147:20 149:6 manager's 28:4,6 39:21 managing 255:11 255:15,17,21 manner 129:22 250:19 manufacture 41:12 88:1 113:1 121:2,9 124:23 139:3 157:11,18 188:9 199:23 214:24 223:2 286:9,12 manufactured 173:9,10 manufacturer 52:20 123:4 manufacturing 4:5 41:9,13 81:17 82:7,7 83:5,17 88:7,12 90:7,15,21 91:5 91:20 94:10,13 94:17 95:9 96:3 105:9 107:3,20 108:10 109:4 110:6 111:3 113:7,14,22 management 44:18 46:2,12 54:11,14 57:11 68:5 88:11 122:2 148:8,14 163:9 197:14,22 198:4	152:16 157:4 161:3 162:16 167:20 173:19 176:4 185:3,7 187:15 188:11 188:16 192:12 201:4 212:20 213:4,5 221:13 221:21 222:4,10 266:5,13 271:13 273:5,10,11,22 274:9,12 275:12 275:22 276:10 276:14 March 107:20,23 108:11 109:6,10 109:23 110:7 154:6 155:7,7 205:13 207:9,17 208:10,17 212:17,21,22 213:4,6,22 221:12,16 275:12,12 mark 10:22 174:5 204:19 marked 10:24 21:8 23:23 37:1 37:5 42:13 46:19 52:11 75:8 80:14 85:10 89:17 97:1 107:4 109:10 110:22 112:6 114:3 115:16 116:18 122:8 125:6 130:21 140:10 144:9 151:5 154:6 155:24 168:23 170:23 171:4 174:11,14 182:10 189:12 189:18 197:8 202:14 205:14 208:10 211:4 214:12 217:1 219:15 223:13 228:17 230:17 233:14 234:11 239:18 245:16 247:11 250:20 252:23 260:12	262:19 market 103:4,22 167:5 marketing 123:23 224:14 markings 171:10 marks 204:16 Marques 2:18 Massachusetts 1:20,22 2:12 7:20 288:3,7 master 210:10,12 material 10:11 159:12,13 160:2 160:17,18 161:5 161:9 matter 7:7 99:13 99:15 103:18 155:16 227:14 265:12 288:13 matters 88:23 103:16 mean 22:5 30:2 31:6 35:18 50:1 50:7 59:5 61:9 63:8 68:15 84:2 119:2 137:15 141:1 160:1 164:5 167:14 171:22 183:8 185:7,12 188:6 205:1 210:4 211:23 220:16 220:24 221:24 222:4 223:6 253:20 254:14 268:7,8 meaning 48:4 76:24 95:11 96:4 100:13 144:20 145:2 190:13 241:7,21 means 10:6,10 24:15 31:14 35:5 64:8 73:16 74:12 157:20,21 160:11,14 164:13,20 184:23 186:2 206:5 207:11 211:22 220:18 221:18 223:9	254:1,12,13,16 meant 19:6 66:20 165:7 175:21 mechanics 185:19 medication 9:22 meet 78:5,6 84:21 87:14 116:6 128:5 meetings 30:18 73:11 77:5 78:2 93:24 127:17 179:6 181:13 182:22 183:13 206:18,21,22 270:15 280:16 282:22 member 2:1,23 32:10,13 35:19 35:21 68:11 members 22:19 24:10,12 30:4 31:7 membranes 76:21 272:7 memo 111:21 112:2 236:7 281:8,10 memories 143:7 memory 66:15 76:2 99:18,24 102:9 106:15,20 110:5,8 126:17 126:24 140:20 141:3,10 143:23 146:8 155:23 157:23 165:14 166:12,15 169:20,21 179:5 179:9 186:9,14 201:24 202:3 203:22 227:11 281:11 mention 51:20 167:8 mentioned 102:5 167:1,15 269:24 Mercantile 47:17 merging 181:10 Messrs 231:8 met 77:9 89:1 110:11,13 135:20 139:24
---	---	--	--	---

140:1 147:5,9 148:18 180:24 methods 173:20 MHB 145:3,4,9,10 148:6 Michael 49:13 54:19 233:10 microcapsulat.. 76:12 microgranulated 82:9 90:9 124:24 microgranulation 81:18 82:10,12 82:13,21 83:1,2 83:5,17 151:18 151:23 Micropellets 209:10 microtablet 209:2 209:3 middle 74:11,16 85:22 102:23 147:16 midway 24:9 137:1 Mike 33:10 42:5 43:9 49:23 50:16 196:12 203:12 211:15,24,24 212:7,8 213:1 223:23 239:10 244:18 253:18 257:3 275:3 million 13:14 44:1 44:14,15,20 45:7 45:18 46:14 48:9 48:17,21 49:1,7 51:14,14,19 112:23 142:15 220:21,24 259:17,21 mind 70:21 107:1 158:4 165:13 179:7 189:9 mindful 15:19 minds 133:10 214:3 mine 117:22 118:2 119:19,21,23 120:3,5 minimum 113:8 minute 92:11	104:15 125:19 175:23 220:15 251:5 253:6 minutes 3:10,12 3:16,24 4:15 6:9 21:8,13,15 23:22 24:2 25:9 42:13 42:15 64:5 85:9 85:13 86:12,12 86:21 89:14 122:8 123:10,19 227:14 230:17 230:21 264:20 mis 93:21 mischaracteriza... 39:23 45:13 64:22 259:6 misleading 29:1 missing 169:2 misspelling 155:19 misspoke 67:3 mistake 37:17 183:10 255:19 misunderstanding 15:21 modification 148:1 161:14 modifications 117:14,18 moment 36:15,18 37:18 84:7 265:17 278:21 281:15,24 283:9 moments 226:7 270:17 money 44:18 46:1 153:1 178:19 259:23 267:14 month 113:2,9 190:24 191:1 198:8,8,8 258:20 258:23 259:2 monthly 112:21 146:21 147:6 months 113:10 145:24 146:23 147:5 149:2 150:14,18,22 191:1 196:19 221:5,7,8,9,11 274:15 275:10 275:14	mother 128:12 motion 13:7,12 move 18:13 207:20 224:22 226:24 moved 18:11 58:14 moving 201:5 Murphy 1:13 3:3 3:8,22 4:3,8,12 4:13,17,19,21 5:6,7,12,19,23 6:3,7,10,16,21 7:7 8:9,15,17 10:23 13:11 24:10 25:8 27:15 30:17 31:24 38:5 38:22 41:17 43:20,24 46:3,9 64:7 67:10 74:13 80:13 85:23 89:16 92:18,23 92:24 93:9 107:14 110:21 115:15,21 116:17 125:5,8 130:20 131:18 134:8 136:5 140:12 144:8 154:14 155:18 165:12 166:2,8,9 170:22 171:3,6 182:9 187:13 201:13 205:12 205:16 213:20 214:10 216:24 226:8 228:10,15 228:16,19 231:8 233:13,16 247:9 253:1 260:10 264:18 265:10 285:23 286:6,19 287:2,19 288:9 Murphy's 22:17 226:3 mutual 100:14 Myers 225:7	12:18,20 16:14 16:18 47:13 70:17,20,21 71:8 78:3 81:4 85:18 108:6 140:8 144:18 155:17 155:20 167:1,8 167:15 168:10 168:18 212:14 225:1,2 named 277:18 names 154:14 155:3,8 156:18 156:18 nations 219:3 nature 58:21 77:2 123:5 125:17 near 217:18 necessarily 31:8 254:12 necessary 41:12 43:4,20 215:17 231:12 necessity 243:21 need 9:9 25:5 43:17 121:22 153:12 195:2 203:20 209:22 210:1,6,9 227:17 229:23 252:10 256:14 264:19 266:11 needed 42:6 138:1 210:13 needs 43:10 198:6 198:12,13 227:11 266:17 negotiate 85:1,5 85:24 86:2 148:7 162:17,18 negotiated 74:18 87:19 120:17 147:18,23 175:18 176:13 negotiates 216:2 negotiating 74:6 91:9,11,13,23 129:11 143:13 147:1 162:15 negotiation 91:18 92:6 101:11 120:8 135:9	negotiations 84:15 88:22 89:6 91:24 100:8 108:7,13 110:6 111:1 116:7 120:13 122:12 129:21 151:1 207:4,8,11 216:12 271:4 272:23 273:1 never 9:4 36:11 64:12,15 68:21 71:21 82:19 91:23 92:1,3 101:14 121:1 167:1 218:15 237:13 238:14 238:12,13 251:22 new 7:2 48:1 58:15 94:24,24 95:5,13,14,15,16 153:6 161:8,13 161:16 164:10 167:21 185:16 185:20,21 193:6 207:15 209:10 210:1 222:15 223:1,6,12 240:22 241:8,12 241:15 242:19 243:2,9,14 246:8 247:24 263:8 268:15 282:8 news 216:22 229:9 243:1 newspaper 166:23 nice 180:17 181:2 251:21,23 nod 9:10 Non 3:20 noncompete 164:17 165:6,18 nondisclosure 76:15 271:20 272:12 nonrenewal 226:19 276:10 276:14 Non-Disclosure 75:7 normal 106:19 normally 86:13
--	--	---	---	---

Page 304

119:3 Nos 3:13 36:23 Notary 1:19 288:6 notation 111:6 112:14 113:13 212:12 note 39:19 43:13 noted 7:4 notes 47:19 114:16 140:16,18 141:1 141:2,4 142:24 143:16 144:4 145:8,11,14 151:11 152:23 163:17 202:9,10 203:11,19,20 210:7 211:8 212:7 213:14 219:18 225:3,12 225:19,22 226:4 226:12 249:15 251:20 288:12 nothing's 198:9 notice 187:14 189:21 196:11 212:18,24 213:8 213:8,15,16 216:14 221:5,7 224:8,11 225:1 235:1 236:10,21 240:13 246:5 264:12 274:13 275:5,11,19 276:9,14 notified 175:19 190:7,14 notifying 110:18 noting 213:12 November 11:15 21:7,20 34:12 65:6 66:22 89:17 187:13 189:6,7 189:11 190:1,11 193:24 194:15 196:10,20 197:7 201:17,22 202:1 202:4 221:4,9 239:14,17 240:8 245:20 247:10 247:15,19 248:2 250:8 263:11 264:8	numbers 65:13,20 NW 2:4 O O 7:1 34:2,3 35:14 35:14,15,15 object 133:8 226:2 231:23 objection 13:21 29:6 31:16 32:7 32:14,21 38:8 39:16,22 40:5,11 40:18,23 43:23 45:12,12,20 48:13 49:6,6,16 50:5,24 51:17,23 57:5,14,16 59:13 59:14,16,17,23 59:24 62:4,4 63:18,19 64:21 84:17,20 93:21 97:24 101:18 103:13 105:17 106:23 121:16 121:18 122:15 124:11 132:15 133:21 153:18 153:18 162:4 166:24 173:14 177:22 194:24 196:21 207:23 210:17 213:24 216:16 220:11 222:11 238:2 244:3 246:12 247:6 248:17 255:16 256:13 256:17 259:4 264:2 268:10 270:8 objective 122:13 146:3 objectives 122:18 147:5,9 obtain 135:3 obviously 80:19 125:13 126:10 131:22 occasion 15:12 83:11 106:4 179:4 259:9,10 occasions 72:14	89:2 125:11 167:24 186:17 occupancy 100:20 occur 94:4 113:9 251:19 occurred 24:24 89:7 94:5 166:10 October 42:12,16 122:7 123:12,19 182:10,18 186:4 186:7 190:10 234:23 235:14 236:7 238:6 offer 25:3 175:1 office 132:6 179:13,14 180:18 184:18 185:9 226:13 officer 12:13 14:12 49:1 279:9 279:18 282:20 283:12 officers 31:2,11 32:20 77:12 231:5,11 offices 1:20 153:24 159:1 183:24 184:24 official 10:15 34:4 47:16 49:15 85:17 99:19 Oh 70:21 79:21 97:8 190:17 194:8 199:8 211:20 221:8 272:9 283:2 Omeprazole/La... 56:9 once 9:13 73:22 205:3 once-a-year 73:21 one's 172:2 open 42:5 43:9 opened 42:10 opening 42:24 operate 57:13 231:9 232:22 operates 52:4 56:20 57:1 operation 13:20 134:24 183:14 183:22,23	216:11 247:21 268:5,6,8 operational 20:3 68:3 201:2 206:3 206:11,20 210:14,18 218:3 218:17 224:21 224:21 operations 34:18 53:5,5 57:9 74:5 74:14 88:15 136:23 137:3,14 137:15,17 138:7 138:11,14 206:5 206:17 207:14 212:2 262:22 263:7 266:12 270:3,5,6,7,10 operations/staff 206:22 opinion 195:19 261:20 opportunities 81:16 163:5 181:7 185:14 opportunity 25:3 47:1 116:5 163:2 183:18,20,21 226:9 opposed 149:7 option 129:9 215:23 options 23:16 24:12,20 25:18 26:3 60:12,13,15 60:15 61:6 69:14 170:2 oral 94:24 95:14 243:18 orally 243:15 263:9 order 22:9 147:9 195:2 275:11 283:20,23 orderly 135:6 orders 113:7,9 ordinary 21:17 organic 164:7 185:14,20 207:16 222:16 223:3,7 organization	58:10 122:21 244:20 organizations 134:16 163:5 organize 201:3 229:10 organized 267:24 orphan 123:24 OTC 52:20,22 ought 113:22 181:8,9 252:14 outside 200:16 overarching 101:15 124:7,12 overdue 134:20 overhead 44:19 183:17 184:20 185:10 266:16 overheads 255:3 oversight 185:2 248:6 249:2 268:20 269:5 owned 64:15 90:24 231:7 232:15,16,21 233:4 235:6 239:2 240:24 241:3,7 242:10 242:15 owners 276:18 ownership 166:15 owning 64:17 owns 232:14 235:13	P P 7:1 8:18 page 3:2,7 4:2 5:2 6:2 11:7,11,11 13:5 16:5 21:11 21:19 22:7 24:8 24:9,18 42:22 52:24 53:4 54:3 54:11 56:7,22 75:20 76:4 85:21 93:4 109:18 114:8 118:4,9,10 118:11,16,19 119:4,6,8,11,17 134:17 136:24 137:1 140:13 143:5 147:16
---	---	---	---	---	--